HIV-2 antigen compositions

ABSTRACT

The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.  
     It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.  
     It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.

[0001] The invention relates to a new class of viruses having the capacity to cause lymphadenopathies, which are then capable of being replaced by acquired immune deficiency syndrome (AIDS) in man. The invention also relates to antigens capable of being recognized by antibodies induced in man by this new class of virus. It also relates to the antibodies induced by antigens obtained from these viruses.

[0002] This invention relates, furthermore, to cloned DNA sequences possessing sequence analogy or complementarity with the genomic RNA of the abovementioned virus. It also relates to the methods for preparing these cloned DNA sequences.

[0003] The invention also relates to polypeptides containing amino acid sequences encoded by the cloned DNA sequences.

[0004] In addition, the invention relates to applications of these antigens to the in vitro diagnosis in man of potentials for certain forms of AIDS and, in respect of some of these antigens, to the production of immunogenic compositions and vaccinating compositions against this retrovirus. The invention likewised relates to the applications of the abovementioned antibodies for the same purposes and, for some of them, to their application to the production of acitve principles of drugs against these forms of human AIDS.

[0005] Finally, the invention relates to the application of the cloned DNA sequences, and of polypeptides obtained from these sequences, as probes in diagnostic kits.

[0006] The isolation and characterization of a first retrovirus, known as LAV, whose responsibility in the developement of AIDS had been recognized, formed the subject of a description in a paper by F. BARRE-SINOUSSI et al. already in 1983 (Science, vol. 220, N^(•) 45-99, 20, p. 868-871). Application of some extracts of this virus, and more especially of some of its proteins, to the diagnosis of the presence of antibodies against the virus was described more especially in European Patent Application n^(•) 138.667. Since then, other similar strains and some variants of LAV have been isolated. Examples which may be recalled are those known by the names HTLV-III and ARV.

[0007] To apply the new rules of nomenclature published in Nature in May 1986, the retroviruses capable of inducing in man the abovementioned lymphadenopathies and AIDS will be given the overall designation “HIV”, an abbreviation of the term “Human Immunodeficiency Virus”. The subgroup of retroviruses formed by LAV and its variants was initially designated by the terms “LAV type I” or “LAV-I”. The latter subgroup will be designated hereinafter HIV-1, it being understood that the term LAV will still be retained to denote that strain, among the strains of retrovirus (in particular LAAV, IDAV-4 and IDAV-2) belonging to the HIV-1 virus class which are described in the abovementioned European Patent Application 138,667, which was used in the comparative experiments described later, namely LAV_(BRU), which was deposited with the Collection Nationale des Cultures de Micro-organismes (CNCM) (National Collection of Micro-organism Cultures) of the Institut Pasteur de Paris, France, on Jul. 15, 1983 under n^(•) I-232.

[0008] The new retrovirus which forms the subject of the present patent and the virus strains which are related to it and which are, like it, capable of multiplying in human lymphocytes, formerly known as. “LAV type II” or “LAV-II”, are henceforward known as “HIV-2”, it being understood that the designations of certain HIV-2 isolates described later will be followed by three letters which refer to the patients from whom they were isolated.

[0009] The “HIV-2” group can be defined as a group of viruses having in vitro a tropism for human T4 lymphocytes, and which have a cytopathogenic effect with respect to these lymphocytes when they multiply therein, and then either cause generalized and persistent polyadenopathies or one of the forms of AIDS. The HIV-2 retroviruses have proved to be different from the HIV-1 type viruses under the conditions mentioned later. Like these latter viruses, they are different from the other human retroviruses which are already known (HTLV-I and HTLV-II).

[0010] Although there is fairly wide genetic variability in the virus, the different HIV-1 strains isolated to date from American, European, Haitian and African patients have antigenic sites in common conserved on their principal proteins, i.e. core protein p25, envelope glycoprotein gp110 and transmembrane protein gp41-43. This relationship makes it possible, for example, for the prototype LAV strain to be used as a strain of antigens for detecting antibodies against all HIV-1 class viruses, in all people who carry them, regardless of their origin. This strain is hence currently used for detecting anti-HIV-1 antibodies in blood donors and patients, in particular by immunofluorescence and in particular by the technique known as ELISA, “Western Blot” (or immuno-imprinting) and “RIPA”, an abbreviation for Radioimmunoprecipitation Assay.

[0011] However, in a serological study peformed with an HIV-1 lysate on patients who originated from West Africa, it was observed that some of them gave seronegative or very weakly positive reactions, whereas they showed clinical and immunological signs of AIDS.

[0012] The cultured lymphocytes of one of these patients were the source of a first HIV-2 retrovirus isolated, whose structure in electron microscopy and whose proteine profile in SDS gel electrophoresis show a resemblance to those of HIV-1. However, this new retrovirus HIV-2 possesses overall only a slight relationship to HIV-1, from the standpoint both of the antigenic homology of its proteins and of the homology of its genetic material.

[0013] This new retrovirus, or retroviruses having equivalent antigenic and immunological properties, can hence constitute sources of antigens for the diagnosis of infection by this virus and the variants which induce an AIDS form of the type which had been observed in the initial instances in African patients or in people who had spent time in Africa.

[0014] Typically, this virus was isolated from the blood, drawn in the presence of heparin, from a 28-year-old heterosexual patient who had never been transfused and who was not a drug addict. Since 1983, he had had substantial chronic diarrhoea, and substantial weight loss (17 kg) with intermittent fever. More recently, he had had Candida and Serratia infections, including an oesophageal candidiasis typical of AIDS.

[0015] This patient also had anaemia, cutaneous anergy, Lymphopenia and a T4 lymphocyte/T8 lymphocyte ratio of 0.15, with a T4 lymphocyte level of less than 100 per mm³ of serum. His lymphocytes in culture did not respond to stimulation with phytohaemagglutinin and concanavalin A. This patient was also diagnosed as suffering from recurrent bacteriaemia due to S. enteriditis, cryptosporidioses, infections due to Isospora belli and cerebral toxoplasmoses.

[0016] This combination of signs was evidence of “complex symptoms linked with AIDS” or “ARC” (abbreviation for “AIDS-Related Complex”), of the type caused by HIV-1 virus. These various observations were also in conformity with the criteria applied by the Center of Disease Control (CDC) of Atlanta, USA.

[0017] The culturing of the lymphocytes from these patients and the isolation of the retrovirus were performed according to the technique already described for the isolation of HIV-1 in the paper by BARRE-SINOUSSI et al. and European Patent Application n^(•) 84/401.834-0.138.667. They are recalled briefly below. Lymphocytes stimulated for 3 days with phytohaemagglutinin (PHA) were cultured in RPMI 1640 culture medium to which 10% of foetal calf serum and 10⁻⁵ M β-mecaptoethanol, interleukin-2 and anti-(human interferon α) serum are added.

[0018] The production of virus was followed by its reverse transcriptase activity. In the culture supernatant, the peak viral activity appeared at between day 14 and day 22, and then decreased. The decline and death of the cell culture followed. As with HIV-1, sections of lymphocytes infected with HIV-2 showed, in electron microscopy, virions which had reached maturity, and viral particles budding at the surface of the infected cells. The cell lines used for producing the cultures of these isolated viruses can be, depending on the case, cell lines of the HUT, CEM or MOLT type, or any immortalized lymphocyte Line bearing T4 receptors.

[0019] The virus was then propagated in cultures of lymphocytes from blood donors, and then in continuous lines of leukaemic origin, such as HUT 78. It was then characterized by its antigens and its nucleic acid as being substantially different from HIV-1. The virus was purified as described in the prior documents already mentioned. A first isolate of this virus was deposited with the CNCM on Dec. 19, 1985 under n^(•) I-502. It was subsequently designated by the name LAV-II MIR. A second isolate was deposited with the CNCM on 21st February 1986 under n^(•) I-352. This second isolate has the reference name LAV-II ROD. These isolates will sometimes be referred to later simply as MIR or ROD.

[0020] In a general manner, the invention relates to any variant of the above viruses, or any equivalent virus (for example, such as HIV-2-IRMO and HIV-2-EHO, deposited with the CNCM on Dec. 19, 1986 under n^(•) s I-642 and I-643, respectively), containing structural proteins which have the same immunological propeties as those of the HIV-2 viruses deposited with the CNCM under n^(•) s I-502 or I-532. The definitions of criteria of equivalence will be returned to later.

[0021] The invention also relates to a method for producing the HIV-2 virus or variants of the latter in permanent cell lines derived from T4 lymphocytes, or lymphocytes bearing the T4 phenotype, this method consisting in culturing these lines which have been infected beforehand with HIV-2 virus and, in particular when the Bevel of reverse transcriptase activity has reached a specified threshold, in recovering the amounts of virus released into the culture medium.

[0022] A preferred permanent line for the purpose of culturing HIV-2 is, for example, of the HUT 78 cell type. An HUT 78 line infected with HIV-2 was deposited on Feb. 6, 1986 with the CNCM under n^(•) I-519. Culturing is, for example, carried out as follows:

[0023] The HUT 78 cells (10⁶/ml) are co-cultured with infected normal human lymphocyte (10⁶/ml). The culture medium is RPMI 1640 with 10% foetal calf serum. After 15 to 21 days, a cytopathogenic effect is observed in the HUT 78 cells. The reverse transcriptase is assayed one week after this observation, in the culture supernatant. It is then possible to begin to recover the virus from this supernatant.

[0024] Another preferred line for culturing belongs to the lines known under the designation CEM.

[0025] The infection and then the culturing of the infected CEM cells can be carried out, in particular, as follows.

[0026] T4 lymphocytes infected beforehand with HIV-2 virus and uninfected cells of the LEM line are co-cultured for the time required for infection of the CEM. The culture conditions are then, moreover, continued in a suitable medium, for example that described below, and when the reverse transcriptase activity of the infected cells has reached a sufficient level the virus produced is recovered from the culture medium.

[0027] In particular, co-culturing was carried out, under the conditions specified below, of human T4 lymphocytes which had been infected five days beforehand with a strain of HIV-2 virus originating from a patient hereinafter designated “ROD”, on the one hand, and CEM, on the other hand.

[0028] The infected T4 lymphocytes, activated beforehand with phytohaemagglutinin, proved to possess a reverse transcriptase activity of 5.000 cpm/10⁶ normal T lymphocytes three days after the beginning of the infection. Culturing was continued until the measured reverse transcriptase activity reached 100.000 cpm in the supernatant. These T4 lymphocytes were then placed in contact with CEM cells (3×10⁶ infected normal T lymphocytes) and reincubated in the following culture medium: RPMI 1640 containing 2.92 mg/ml of L-glutamine, 10% of decomplemented foetal calf serum, 2 ug/ml of Polybrene, 0.05% of anti-interferon-alpha serum, 100.000 ug/ml of penicillin, 10 ug/ml of streptomycin and 10.000 ug/ml of neomycin.

[0029] The culture medium is changed twice weekly.

[0030] The measurements of reverse transcriptase activity measured in the supernatant were as follows: on day 0    1,000 (background) on day 15   20,000 on day 21   200,000 on day 35 1,000,000

[0031] A CEM culture infected with HIV-2 virus was deposited with the Collection Nationale de Cultures de Micro-organismes (CNCM) of the Institut Pasteur under n^(•) I-537 on March 24, 1986.

[0032] A few characteristics of the antigens and nucleic acids involved in the structure of HIV-2 emerge from the experiments carried out under the conditions described below. They will, in many cases, be better assessed by comparison with the same type of characteristics relating to other types of retrovirus, in particular HIV-1 and SIV.

[0033] In that which follows, reference will be made to the drawings, in which:

[0034]FIGS. 1a, 1 b and 1 c relate to crossed immuno-precipitation experiments between sera, respectively, of patients affected with HIV-1 and HIV-2, and of rhesus monkeys infected with STLV-III, on the one hand, and viral extracts of HIV-1, on the other hand;

[0035]FIGS. 2a and 2 b show comparative results for the electrophoretic mobilities of the proteins of HIV-1, HIV-2 and STLV-III respectively, in SDS-polyacrylamide gels;

[0036]FIG. 3 shows the results of crossed hybridization between genomic sequences of HIV-1, HIV-2 and STLV-III on the one hand, and probes containing different subgenomic sequences of the HIV-1 virus, on the other hand;

[0037]FIG. 4 is a restriction map of the cDNA derived from the RNA of HIV-2 ROD;

[0038]FIG. 5 is a restriction map of an E2 fragment of the cDNA derived from HIV-2, this fragment containing a region corresponding to the 3′ LTR region of HIV-2;

[0039]FIG. 6 is a nucleotide sequence of a portion of E2, this sequence corresponding to the U3/R region of HIV-2;

[0040]FIG. 7 shows:

[0041] on the one hand, and schematically, structural elements of HIV-1 (FIG. 7A) and, aligned with a region containing the HIV-1 3′ LTR, the sequence derived from the E2 region of the HIV-2 cDNA, and

[0042] on the other hand, the common nucleotides present, respectively, in the sequence derived from the E2 region of HIV-2 and in the corresponding sequence of HIV-1, placed in alignment at the cost of a number of deletions and insertions (FIG. 7B);

[0043]FIG. 8 shows schematically the structures of several clones of a phage modified by several inserts originating from the cDNA derived from HIV-2 (clones ROD4, ROD27 and ROD35); sequences derived, in their turn, from ROD4, ROD27 and ROD35, subcloned in a plasmid pUC18, have also been shown schemetically in this figure, these latter sequences being placed to correspond with the regions of ROD4, ROD27 and ROD35 from which they respectively originate;

[0044]FIG. 9 shows the relative intensities of hybridization between

[0045] a/ eleven fragments removed from different regions of the complete HIV-1 genome (the fragments being shown schematically at the bottom of the figure), on the one hand, and the HIV-2 cDNA, present in ROD4, on the other hand, and

[0046] b/ fragments originating from HIV-2 with the same cDNA.

[0047] Generelly, the HIV-2 antigens used in the comparative tests, the description of which follows, originate from the HIV-2 MIR strain deposited with the CNCM under n^(•) I-502, and the DNA sequences derived from the genomic DNA of HIV-2 originate from the strain HIV-2 ROD deposited with the CNCM under n^(•) I-352.

[0048] I-Antigens, in Particular Proteins and Glycoproteins

[0049] The virus initially cultured,in HUT 78 was labelled metabolically with [³⁵S]systeine and [³⁵S]methionine, the infected cells being incubated in the presence of these radioactive amino acids in culture medium devoid of the corresponding unlabelled amino acid, for a period of 14 to 16 hours, especially according to the technique described in the paper designated as reference (21) in the bibliography presented at the end of the description, as regards the labelling with [³⁵S]cysteine. The supernatant is then clarified and the virus then ultracentrifuged for one hour at 100.000 g on a cushion of 20% sucrose. The principal antigens of the virus separated by electrophoresis in a polyacrylamide gel (12.5%) under denaturing conditions (SDS), or in a gel composed of poly-acrylamide (10%)+bisacrylamide (0.13%) with SDS (0.1% final concentration). The following coloured markers are used as molecular weight references: myosin:  200 kd phosphorylase B: 97.4 kd BSA:   68 kd ovalbumin:   43 Kd α-chymotrypsin: 25.7 kd β-lactoglobulin: 18.4 kd lysozyme: 14.3 kd

[0050] Other molecular weight markers were used in other experiments. This applies, in particular, to FIGS. 1a, 1 b and 1 c, which refer to other known molecular weight markers (under the letter M in these figures). The antigens are still more readily distinguished after immuno-precipitation (RIPA) or by immuno-imprinting (Wastern blot), using the antibodies present in the patient's serum: their apparent molecular weights, determined by their apparent migrations, are very close to those of the HIV-1 antigens.

[0051] It is generally specified that, in the text which follows, the numbers which follow the designations “p” and/or “gp” correspond to the approximate molecular weights of the corresponding proteins and/or glycoproteins, divided by 1000. For example, p36 has a molecular weight of the order of 36.000. It is, however, understood that these molecular weight values can vary within a range which can reach 5%, 10% or even more, depending on the techniques used for the determination of these molecular weights.

[0052] Repetition of the experiments enabled the apparent molecular weights of the HIV-2 antigens to be determined more accurately. Thus, it was found that the molecular weights of the three core proteins, which had initially been assigned molecular weights of the order of 13.000, 18.000 and 25.000, respectively, in fact had apparent molecular weights closer to the following values: 12.000, 16.000 and 26.000, respectively. These proteins are hereinafter designated by the abbreviations p12, p16 and p26.

[0053] The same considerations apply to the existence of protein or glycoprotein bands whose apparent molecular weights were assessed at values which could range from 32.000 to 42.000-45.000. Repetition of the measurements finally enabled a band corresponding to an apparent molecular weight of 36.000 to be precisely defined. In the text which follows, this band is designated by the abbreviation p36. Another band at 42.000-45.000 (p42) is consistently observed also. One or other of p36 or p42 probably constitutes a transmembrane glycoprotein of the virus.

[0054] A major envelope glycoprotein having a molecular weight of the order of 130-140 kd is consistently observed: this glycoprotein is designated hereinafter by the term gp140.

[0055] It is appropriate to note that, in general, the molecular weights are assessed with an accuracy of ±5%, this accuracy even being capable of becoming a little lower for antigens of high molecular weight, as was fournd for gp140 (molecular weight of 140±10%). This group of antigens (when they are labelled with [³⁵S]cysteine is only faintly recognized, if at all, by sera of patients containing anti-HIV-1 antibodies in the detection systems used in the laboratory or by the use of tests employing HIV-1 lysates, such as those marketed by DIAGNOSTICS PASTEUR under the name “ELAVIA”. Only the p26 protein was weakly immunoprecipitated by such sera. The envelope protein was not precipitated. The serum of the patient infected with the new virus (HIV-2) faintly recognizes a p34 protein of HIV-1. In the detection system used, the other HIV-1 proteins were not recognized.

[0056] In contrast, HIV-2 possesses some proteins which show some immunological relationship with comparable structural proteins or glycoproteins, separated under similar conditions from a retrovirus recently isolated from captive macaques of the rhesus species, whereas this immunological relationship tends to become obliterated for other proteins or glycoproteins. This latter retrovirus, which is presumed to be the aetiological agent of AIDS in monkeys, was designated by the investigators who isolated it [bibliographic references (16-18) below] by the name “STLV-III_(mac)”. For convenience of reference, it will be designated in the text which follows simply by the term “STLV-III” (or alternatively by the term SIV, an abbreviation for “Simian Immunodeficiency Virus”).

[0057] Another retrovirus, designated “STLV-III_(AGM)” or SIV_(AGM)), has been isolated in wild green monkeys. However, in contrast to the virus present in rhesus monkeys, the presence of “STLV-III_(AGM) ” does not appear to induce an AIDS-type disease in African green monkeys.

[0058] Nevertheless, the immunological relationship of the structural proteins and glycoproteins of HIV-2 on the one hand and the STLV-III_(mac) and STLV-III_(AGM) retroviruses on the other hand, and consequently the relationship of their nucleic acid sequences, remains limited. Experiments have enabled a first distinction to be established between the retroviruses capable of infecting man or monkeys; the following emerges;

[0059] The HIV-2 virus does not multiply in chronic fashion in the lymphocytes of rhesus monkeys when it has been injected in vivo and under working conditions which permit the development of the STLV-III_(mac) virus, as have been described by N. L. Letvin et al., Science (1985), vol. 230, 71-75.

[0060] This apparent inability of HIV-2 to develop in monkeys under natural conditions enables the HIV-2 virus, on the one hand, and the STLV-III virus isolates, on the other hand, to be differentiated biologically.

[0061] Employing the same techniques as those recorded above, it was found that it was also possible to obtain the following from STLV-III:

[0062] a principal p27 core protein, having a molecular weight of the order of 27 kilodaltons,

[0063] a major envelope glycoprotein, gp140,

[0064] a p32 protein, probably transmembrane, which is not observed in RIPA when the virus has been labelled beforehand with [³⁵ S]cysteine, but which can be observed in immuno-imprinting experiments (Western blots) in the form of broad bands.

[0065] The major envelope glycoprotein of HIV-2 has proved to be immunologically closer to the major envelope glycoprotein of STLV-III than to the major envelope glyco-protein of HIV-1.

[0066] These findings apply not only in respect of the molecular weights, 130-140 kilodaltons for the major glycoproteins of HIV-2 and STLV-III compared with approximately 110 for the major envelope glycoprotein of HIV-1, but also in respect of the immunological properties, since sera drawn from patients infected with HIV-2, and more especially antibodies formed against the HIV-2 gp140, recognize the STLV-III gp140 whereas, in comparable experiments, the same sera and the same antibodies to HIV-2 do not recognize the HIV-1 gp110. However, anti-hiv-2 do not recognize the HIV-1 gp110. However, anti-HIV-1 sera which have never reacted with the HIV-2 gp140s precipitate a [³⁵S]cysteine-labelled 26 kd protein present in extracts of HIV-2.

[0067] The major core protein of HIV-2 appears to have an average molecular weight approximately 26.000) intermediate between that of the HIV-1 p25 and the p27 of STLV-III.

[0068] These observations are derived from experiments carried out with viral extracts obtained from HIV-2 isolated from one of the abovementioned patients. Similar results have been obtained with viral extracts of HIV-2 isolated from the second patient.

[0069] Cells infected, respectively, with HIV-1, HIV-2 and STLV-III were incubated in a medium containing 200 μCi/ml of [³⁵S]cysteine in a medium free from unlabelled cysteine for 16 hours. The clarified supernatants were centrifuged at 60.000 g for 90 minutes. The pellets were lysed in an RIPA buffer (1), immunoprecipitated with different sera and then subjected to electrophoresis on polyacrylamide gel charged with sodium dodecyl sulphate (SDS-PAGE).

[0070] The results observed are illustrated by FIGS. 1a, 1 b and 1 c.

[0071]FIG. 1a shows the observed results of immuno-precipitation between a viral extract of HIV-1 obtained from a CEM C1.13 cell line and the following sera, respectively:

[0072] anti-HIV-1-positive serum (band 1),

[0073] serum obtained from the first patient mentioned above (band 2),

[0074] serum of a healthy African carrier of anti-HIV-1 antibodies (band 3),

[0075] serum obtained from a macaque infected with STLV-III (band 4), and

[0076] serum of the second patient mentioned above (band 5).

[0077] In FIG. 1b, there are recorded the observed results of immunoprecipitation between the HIV-2 antigens obtained from the first patient, after prior culture with HUT-78 cells, and different sera, more especially the serum of the abovementioned first patient (band 1), the anti-HIV-1-positive serum (band 2), the serum of the macaque infected with STLV-III (band 3) and the serum of the abovementioned second patient (band 4).

[0078] Finally, FIG. 1c illustrates the observed results of immunoprecipitation between the antigens of an STLV-III isolate obtained from a macaque having a simian AIDS. The sera used, to which the bands 1 to 5 refer, are the same as those recorded above in relation to FIG. 1a.

[0079] M refers to the markers myosin (200 kd), galactosidase (130 kd), bovine serum albumin (69 kd), phosphorylase B (93 kd), ovalbumin (46 kd) and carbonic anhydrase (30 kd).

[0080]FIGS. 2a and 2 b show comparative results for the electrophoretic mobilities of the proteins of HIV-1, HIV-2 and STLV-III.

[0081]FIG. 2a relates to the experiments carried out with extracts of virus labelled with [³⁵S]ψysteine, after immunoprecipitation on SDS-PACE. The different bands relate to the following virus extracts: virus obtained from patient 1 and immunoprecipitated by the serum originating from the same patient (band 1), extract of the same virus immunoprecipitated with a negative control serum originating from a person not carrying anti-HIV-1 or anti-HIV-2 antibodies (band2), extract of STLV-III virus immunoprecipitated with a serum originating from a macaque infected with STLV-III (band 3), immunoprecipitation observed between extracts of the same virus and a negative control serum (band 4), and extract of HIV-1 immunoprecipitated with the serum of a European patient infected with AIDS.

[0082]FIG. 1b shows the results obtained in Western blot (immuno-imprinting) experiments. Cell lysates originating from uninfected or infected HUT-78 cells were subjected to electrophoresis on SDS-PAGE, and then transferred electrophoretically to a nitrocellulose filter before being reacted with the serum of the above-mentioned first patient (serum diluted {fraction (1/100)}). The nitrocellulose filter was then washed and the detection of the bound antibodies visualized with ¹²⁵I-labelled goat anti-human IgG.

[0083] The spots observed in bands 1, 2 and 3 relate, respectively, to the agglutination experiments between the abovementioned serum and extracts of uninfected HUT-78 cells (band 1), extracts of HUT-78 cells infected with an HIV-2 virus (band 2) and extracts of HUT-78 cells infected with STLV-III (band 3). The numbers which appear in the margins beside each of the bands correspond to the approximate molecular weights of the most representative viral proteins (molecular weights in kilodaltons).

[0084] II-Nucleic Acids

[0085] 1/The RNAs of the HIV-2 Retrovirus

[0086] The RNA of the virus, deposited on a filter according to the “spot blot” technique, did not hybridize, under stringent conditions, with the DNA of HIV-1.

[0087] By “stringent conditions”, there are understood the conditions under which the hybridization reaction between the RNA of the HIV-2 and the chosen probe, radio-actively labelled with ³²p (or labelled in a different manner), followed by the washing of the probe, are carried out. The hybridization, on a membrane, is carried out at 42° C. in the presence of an aqueous solution particularly of 50% formamide (volume/volume) in 0.1% SDS/5×SSC for 18 hours. The membrane on which the hybridization reaction has been carried out is then washed at 65° C. in a buffer containing 0.15% of SDS and 0.1×SSC.

[0088] By “non-stringent conditions”, there are understood the conditions under which the hybridization reaction and the washing are carried out. The hybridization is carried out by bringing into contact with the chosen probe, labelled with ³²P (or otherwise labelled), namely at 42° C. in a 5×SSC buffer, 0.1% SDS, containing 30% of formamide for 18 hours. The washing of the membrane is carried out at 50° C. with a buffer containing 0.1% of SDS and 2×SSC.

[0089] Hybridization experiments were also carried out with a hybridization probe consisting of a recombinant plasmid pBT1 obtained by cloning the DNA of HIV-1 originating from λJ19 (Cell 1985, vol. 40, p. 9) in the vector pUC18. Under non-stringent conditions, only very weak hybridization was observed between the RNA of HIV-2 and the cloned DNA derived from HIV-1.

[0090] Other probes containing cloned sequences of HIV-1 were used:

[0091] a/single-stranded probes of subgenomic DNA of HIV-1, produced from subclones of the HIV-1 genome and inserted in phage M13. The cloned regions related to the protease gene or the % endonuclease” gene.

[0092] Only one probe of the endonuclease region of HIV-1 (nucleotide sequence between bases n^(•)s. 3760 and 4130) gave a weak hybridization under non-stringent conditions with HIV-2. The “protease” probe (HIV-1 nucleotide sequence between bases n^(•)s. 1680 and 1804) did not hybridize even under non-stringent conditions with HIV-2.

[0093] b/A probe pRS3, consisting of the sequence coding for the “envelope” region of HIV-1 (subcloning in pUC18) did not give hybridization under non-stringent conditions with HIV-2.

[0094] The “spot blot” technique is also known as “dot blot” (transfer by spots).

[0095] Further results of hybridization between genomic RNAs of HIV-1, HIV-2 and STLV-III, on the one hand, and probes containing different subgenomic sequences of the HIV-1 virus, on the other hand, appear in FIG. 3.

[0096] The supernatants of the different culture media (in the proportion of 0.5 to 1 ml for each spot) were centrifuged for 5 minutes at 45.000 revolutions per minute; the pellets were resuspended in an NTE buffer containing 0.1% of SDS and deposited on a nitrocellulose filter. The latter was pre-soaked in a 2×SSC medium (0.3 M NaCl, 0.03 M sodium citrate). After baking (for 2 hours at 80° C.), the filters were hybridized with various probes contraining genomic sub-fragments of HIV-1, under non-stringent conditions (30% formamide, 5×SSC, 40° C.), washed at 50° C. with a 2×SSC solution containing 0.1% of SDS and then autoradiographed for 48 hours at −70° C. with enhancing screens.

[0097] The probes 1-4 are single-stranded probes obtained by the “prime cut” method as described in (25). Briefly, the single-stranded fragments originating from the M13 virus and bearing subgenomic HIV-1 inserts (30) were ligated to oligomeric fragments (17 nucleotides) originating from M13 (BIOLABS). The complementary strand was then synthesized with Klenow enzyme in a TM buffer (10 mM Tris, pH 7.5, 10 mMMgCl₂) in the presence of dATP, dGTP, dTTP and dCTB, labelled with ³²P at the alpha-position (Amersham, 3000 Ci/mmol). The DNA was then digested with the appropriate restriction enzymes, heat denatured and subjected to electrophoresis on a denaturing polyacrylamide gel (containing 6% of acrylamide, 8 M urea in a TDE buffer). The gel was then autoradiographed for 5 minutes. The probe was then cut out and eluted in a 300 mM NaCl, 0.1% SDS buffer. Specific activities (SA) of these single-stranded probes were estimated at 5×10⁸-10⁹ disintegrations per minute/microgram (dpm/ug).

[0098] The characteristic sequences present in the different probes were as follows:

[0099] Probe 1: nucleotides 990-1070,

[0100] Probe 2: nucleotides 980-1260,

[0101] Probe 3: nucleotides 2170-2240

[0102] Probe 4: nucleotides 3370-3640.

[0103] The numbering of the above nucleotides are those envisaged in the paper under reference (30).

[0104] Lastly, the probe 5 consists of a plasmid pUC18 bearing the EcoR1-Sac1 fragment of the HIV clone in λJ19 (31), which was subjected to nick translation to obtain an SA of approximately 10⁸ dpm/μg.

[0105] The relative arrangements of the subgenomic fragments present in the probes with respect to the whole HIV-1 genome are shown schematically in FIG. 3. The different spots correspond, respectively, as follows:

[0106] spot A: a virus is obtained from a culture of CEM C1.13 cells infected with HIV-1,

[0107] spot B: a virus is obtained from HUT-78 cells infected with STLV-III,

[0108] spots C and D: isolates obtained, respectively, from the viruses of the abovementioned two African patients,

[0109] spot E: negative control cell extract obtained from uninfected HUT-78 cells,

[0110] spot F: virus obtained from a patient from Zaïre suffering from AIDS, which had been cultured in normal T lymphocytes in the presence of TCGF.

[0111] All the spots were obtained with an amount of virus corresponding to 25.000 dpm of reverse transcriptase activity, except for the spots C: 15.000 dpm.

[0112] The following observations were made:

[0113] The genomic RNAs of the two HIV-2 isolates obtained from purified viral particles did not hybridize with any of the probes under the stringent conditions described above, although the viral particles were isolated and purified from culture supernatants of highly infected cells showing evidence of high reverse transcriptase activity.

[0114] Under the non-stringent conditions described above, the following observations were made: all the probes hybridized intensely with the genomic RNAs obtained from the control HIV-1 preparations and from another isolate obtained from a patient from Zaïre suffering from AIDS.

[0115] Two of the probes obtained (nucleotides 990-1070 and 990-1260, both originating from the gag region of HIV-1) hybridized slightly with the spots from extracts of the HIV-2 retroviruses; only one of these two probes (nucleotides 990-1260) also showed slight hybridization with the STLV-III spot (FIG. 3). As regards the probe containing a fragment of the pol region (nucleotides 2170-2240), hybridization was observed with STLV-III and, albeit much more weakly, with the RNA of HIV-2. The other probe of the pol region (nucleotides 3370-3640) did not give hybridization with any of the HIV-2 and STLV-III spots.

[0116] Lastly, the probe modified by nick translation and containing the entire env gene and the LTR (nucleotides 5290-9130) of HIV-2 did not hybridize either with the RNAs of STLV-III or with those of HIV-2.

[0117] It will also be noted that anoter probe which contained the 5′ end of the pol reading frame of HIV-1 (corresponding to the protease region) did not hybridize either with the RNAs of HIV-2 or with the RNAs of STLV-III.

[0118] It consequently also results from the foregoing that the HIV-2 virus appears more remote, from the structural standpoint, from the HIV-1 virus than it is from STLV-III. HIV-2 nevertheless differs significantly from STLV-III, which bears out the different results observed in respect of the infective capacities of the HIV-2 viruses, which are virtually nil in monkeys, compared with the unquestionable ineffective capacities of STLV-III viruses in these same specites of monkeys.

[0119] The restriction maps and the genomic RNA sequences of HIV-2, or of the cDNAs obtained from these genomic RNAs are accessible to those versed in the art, since the strains of HIV-2 deposited with the CNCM can, after suitable multiplication, provide him with the genetic equipment required for the determination of these restriction maps and nucleotide sequences. The conditions under which the restriction map of the genome of one of the HIV-2 isolates of this invention were established, and the conditions under which certain portions of cDNA derived frog these genomes were sequenced, are described below.

[0120] The restriction map of the genome of a retrovirus which is representative of HIV-2 retroviruses is shown in FIG. 4. The restriction map of a substantial fragment of this cDNA is shown in FIG. 5. Finally, a portion of this latter fragment has been sequenced.

[0121] This sequence, and a number of the restriction sites which it contains, are shown in FIG. 6. The cloned whole cDNA—or cloned fragments of this cDNA—can themselves be used as specific hybridization probes.

[0122] 2/cDNA and Fragments of this cDNA Derives, Respectively, from the RNA of HIV-2

[0123] The conditions under which the abovementioned cDNA was obtained are described below.

[0124] The first stage of manufacture of this cDNA comprised the production of an oligo(dT) serving as a primer or of an initiator cDNA strand, by carrying out an endogenous reaction activated by a detergent, using the reverse transcriptase of HIV-2, on purified virions obtained from supernatants of infected CEM cells. The CEM cell line was a lymphoblastoid CD4+cell line described by G. E. Foley et al. in Cancer 18:522-529 (1965), which is considered to be incorporated herein by reference. These CEM cells used are infected with an ROD isolate, which was shown to produce substantial amounts of HIV-2 continuously.

[0125] After the synthesis of the second strand (in the presence of nucleotides and a bacterial DNA polymerase), the double-stranded cDNAs were inserted into a bacterial phage vector M13 TG130. A phage library of 10⁴ recombinant M13 phages was obtained and subjected to an in situ screening with an HIV-1 probe. The latter contains a 1.5 kb fragment originating from the 3′ end of the cDNA derived from the RNA of the LAV isolate (shown in FIG. 7A). Approximately 50 positive plaques Were detected, purified and characterized by crossed hybridization of the inserts and sequencing of the ends.

[0126] This procedure enabled different clones to be isolated, containing sequences approximately complementary to the 3′ end of the polyadenylated RNA of the LTR [abbreviation for “long terminal repeat” of HIV-1, described by S. Wain Hobson et al. in Cell 40:9-17 (1985)] region, considered to be incorporated herein by reference.

[0127] The largest of the inserts of the group of M13 clones in question, which hybridize with the 3′ LTR region of HIV-1, is an approximately 2 kb clone designated E2. Like the 3′ LTR region of HIV-1, the clone E2 contains an AATAAA signal situated approximately 20 nucleotides upstream from a poly(A) terminal portion, and a 3′ LTR region corresponding to that of HIV-2. After partial sequencing, this 3′ LTR region of HIV-2 proved to possess a distant relationship with the homologous region of HIV-1.

[0128]FIG. 5 is a restriction map of the fragment of E2 (elongated rectangular area) incorporated in plasmid pSPE2 which contains it. It comprises part of the R region and the U3 region of HIV-2. The drawing does not show the boundaries of the R and U3 regions.

[0129] The sequence of part of E2 is shown in FIG. 6. The positions of specific restriction sites are indicated therein. The small degree of relationship between the 3′ LTR regions of HIV-1 and HIV-2 is illustrated in FIG. 7. In effect, only approximately 50% of the nucleotides of the two LTR sequences can be placed in alignment (approximately 50% sequence homology), at the cost of some insertions or deletions. In comparison, the sequence homology of the corresponding regions of the different variant American and African isolates of HIV-1 is greater than 95%, without insertion or deletion.

[0130] The clone E2 was used as a specific probe for HIV-2, for the identification on a hybridization filter of the sequences originating from HIV-2 and present in other clones.

[0131] This probe also detects the genomic RNA of HIV-2 under stringent conditions. It likewise permits detection, by the so-called “Southern blot” method on the DNA of CEM or similar cells infected with an ROD isolate or with other HIV-2 isolates. No signal is detected under the same stringency conditions in tests of hybridization of this probe with cDNAs originating from uninfected cells or from cells infected with HIV-1. These results confirmed the exogenous nature of HIV-2 with respect to HIV-1. An approximately 10 kb species, probably corresponding to the non-integrated viral DNA, was detected as a principal constituent in the undigested DNA of cells infected with HIV-2. Anoter DNA having an apparent size of 6 kb, possibly corresponding to a circular form of the viral DNA, was also detected.

[0132] The other portions of the HIV-2 genome were also identified. For this purpose, a genome library was constructed in phage lambda L47. Phage lambda L47.1 has been described by W. A. M. Loenen et al. in Gene 10 249-259 (1980), which publication is considered to be incorporated herein by reference.

[0133] The genome library is constructed with fragments obtained by digestin of the DNA originating from the CEM cell line infected with HIV-2 ROD, after digestion with the enzyme Sau3AI.

[0134] Approximately 2×10⁶ recombinant plaques were screened in situ with a clone containing the labelled E2 insert of the HIV-2 cDNA. Ten recombinant phages were detected on plaques and purified. The restriction maps of three of these phages, characterized by their capacity for “Southern blot” hybridization with the E2 insert under stringent conditions, as well as with subgenomic probes of HIV-1 under non-stringent conditions.

[0135] A clone bearing a 9.5 kb insert and derived from the whole circular viral DNA, containing the complete HIV-2 genome, was identified. It was designated “Lambda ROD 4”. The other two clones, Lambda ROD 27 and Lambda ROD 35, derived from integrated proviruses, bear LTR sequences of the viral coding sequences and adjacent cell DNA sequences. The different sequences are shown in FIG. 8.

[0136] Fragments of the Lambda clones were subcloned in plasmid vector pUC18. The fragments originating from λ ROD 4, λ ROD 27 and λ ROD 35, and subclones respectively, in the abovementioned plasmid vector, are also seen in FIG. 8. The following sublclones were obtained:

[0137] pROD 27-5, derived from Lambda ROD 27, contains a 5.2 kb region of the HIV-2 genome and adjacent cell sequences (5′ LTR and 5′ coding viral sequence around an EcoRI site);

[0138] pROD 4.8, derived from Lambda ROD 4, contains an approximately 5 kb HindIII fragment. This fragment corresponds to the central portion of the HIV-2 genome;

[0139] pROD 27-5′ and pROD 4.8 contain HIV-2 inserts chich overlap each other;

[0140] pROD 4.7 contains a 1.8 kb HindIII fragment of Lambda ROD 4; this fragment is placed in the 3 direction with respect to the subcloned fragment in pROD 4.8, and contains approximately 0.8 kb of coding viral sequences and a portion situated between the BamHI and HindIII cloning sites of the left arm of phage Lambda (Lambda L 47.1);

[0141] pROD 35 contains all the HIV-2 coding sequences in the 3 direction with respect to the EcoRI Site, the 3′ LTR end and approximately 4 kb of adjacent nucleotide sequences of cellular origin;

[0142] pROD 27-5′ and pROD 35, present in E. coli HB 101, were deposited on Nov. 21, 1986 with the CNCM under I-626 and I-633;

[0143] pROD 4.7 and pROD 8, present in E. coli TG1, were deposited on Nov. 21, 1986 with the CNCM, respectively, under n^(•)s I-627 and I-628.

[0144] The complete HIV-2 ROD genome, the restriction map of which is seen in FIG. 4, was reconstituted from pROD 35, linearized beforehand with EcoRI, and pROD 27-5′. The EcoRI insert of pROD27-5 was ligated in the correct orientation in the EcoRI site of pROD 35.

[0145] The degree of relationship between HIV-2 and the other human or simian retroviruses was assessed by mutual hybridization experiments. The relative homology between the different regions of HIV-1 and HIV-2 genomes was determined by tests of hybridization of fragments originating, respectively, from cloned HIV-1 genome and from radioactively labelled lambda ROD 4. The relative positions of these fragments (numbered from 1 to 11) with respect to the HIV-1 genome are seen at the bottom of FIG. 9.

[0146] Even under very low stringency conditions (Tm-42° C.), the HIV-1 and HIV-2 genomes hybridize only at the level of their respective gag genes (spots 1 and 2), reverse transcriptase regions in pol (spot 3), end regions of pol, Q (or sor) genes (spot 5) and F (or 3′ orf) genes and 3′ LTR (spot 11). The HIV-1 fragment used for detecting the first cDNA clones of HIV-2 corresponds to the subclone of spot 11, which hybridizes relatively well with HIV-2 under non-stringent conditions. A signal originating from spot 5 is the only one which persists after stringent washing. The envelope gene, the tat gene region and part of pol appear to be highly divergent. These data, as well as the sequence obtained with LTR (FIG. 3), demonstrate that HIV-2 is not (at all events, as regards its envelope) a variant of HIV-1.

[0147] It is observed that HIV-2 is more closely related to SIV [described by M. D. Daniel et al in Science 228:1201-1204 (1985)], which must be considered to be incorporated herein by reference] than it is to HIV-1.

[0148] All the proteins of SIV, including the envelope protein, are immunoprecipitated by sera of patients infected with HIV-2, while the serological cross-reactivity of HIV-1 and HIV-2 is limited to the core proteins. However, SIV and HIV-2 can be distinguished by the differences mentioned above in respect of the molecular weights of their proteins.

[0149] As regards the nucleotide sequences, it is also noted that HIV-2 is related to SIV.

[0150] Furthermore, the characterization of HIV-2 also makes it possible to demarcate the region of the envelope glycoprotein which is responsible for the binding of the virus to the surface of the target cells and the subsequent internalization of the virus. The interaction takes place via the CD4 molecule itself, and it appears that HIV-1 and HIV-2 use the same receptor. Thus, although there are large differences between the env genes of HIV-1 and 2, the restricted homologous regions of the envelopes of the two forms of HIV can be considered to be constituents of binding to a common receptor of T4 lyphocytes. These sites are called on to form epitopes bearing the immunogenicity of peptides which might be used to elicit in man a protective immunoresponse against HIV viruses.

[0151] Advantageous sequences for forming probes in hybridization reactions with the genetic material of patients carrying viruses or proviruses, in particular for detecting the presence of HIV-2 virus RNA in their lymphocytes, contain a nucleotide sequence resulting from the combination of 5 kb HindIII fragments of ROD 4 and E2 cDNA. The experiments can be carried out by all methods, in particular by the “Northern blot”, “Southern blot” and “dot blot” techniques.

[0152] Further characteristics of the invention will also emerge, without implied limitation, in the course of the description which follows of examples of identification of certain portions of the retroviral genome and of the production of a number of recombinant DNAs involving various portions of a cDNA derived from the retroviral genome of HIV-2.

EXAMPLES Example I DNA Probe, for Use in Kits for Diagnosis of HIV-2

[0153] A cDNA complementary to the genome RNA, obtained from purified virions was prepared by the following method:

[0154] The supernatant obtained after 48 hours' culturing of CEM cells infected with an HIV-2 ROD isolate of HIV-2 was ultracentrifuged. The centrifugation pellet containing the virion was centrifuged on a sucrose gradient to form a new centrifugation pellet, substantially by the same method as that described in European Patent Application 84/401.234-0.138.667, already mentioned.

[0155] The purified HIV-2 preparation was used for the synthesis of cDNA, employing an endogenous reaction activated by a detergent.

[0156] In summary, the virion preparation was added to a reaction mixture containing 50 mM Tris-HCL, 5 mM MgCl₂, 10 mM DTT, 0.025% of the detergent marketed under the name TRITON, and 50 μM of each of the 4 deoxynucleoside triphosphates and an oligo(dT) initiator. The reaction was carried out for 90 minutes at 37° C.

[0157] After extraction with phenol of the proteins present in the first reaction medium, the second cDNA chain was synthesized in the presence of RNAse, E. coli DNA polymerase 1 and the 4 deoxynucleotides, for 1 hour at 15° C. and 1 hour at 22° C. Blunt ends were created on this double-stranded cDNA by the action of T4 DNA polymerase. All the reagents for this procedure are commercially available (AMERSHAM cDNA kit) and were used as recommended by the supplier.

[0158] After (1) ligation of adapters (linkers) containing an EcoRI site (marketed by Pharmacia) to the blunt ends of the cDNA in the presence of a T4 DNA ligase (marketed by BIOLABS), (2), digestion of these linkers with the restriction endonuclease EcoRI, and (3) removal of the linker fragments by gel filtration (gel column marketed under the name ULTROGEL) on AcA 34 (LKB-IBF), the cDNA is inserted in an M 13 TG 130 vector cleaved with EcoRI. A library of cDNAs was obtained after transformation of E. coli strain TG1. Approximately 10⁴ recombinant M13 plaques were obtained.

[0159] To select, in the cDNA library, recombinant M13 clones containing the HIV-2 cDNA, the technique of plaque hybridization was used. The DNA of the M13 plaques was transferred to nitrocellulose filters and hybridized with subgenomic HIV-1 probes derived from the “lambda J19” clone of an LAV (or HIV) virus decribed in the European patent application. This probe contained an insert consisting of a portion having an approximate length of 1500 base pairs (bp) of HIV-1 DNA. This insert was bounded by two HindIII restriction sites, respectively, inside the open reading frame of the “env” gene and in the R segment of the 3′ LTR end of HIV-1. This probe contained the 3′ end of the env gene, the whole F gene, the U3 segment and a portion of the R segment of the LTR, having an approximate length of 1500 base pairs (bp).

[0160] The probe containing the 1.5 kg HindIII insert was labelled with [³²P]-dCTP and -dTTP (3000 Ci×10⁻³ mole) by incubating the probe in the presence of initiators and Klenow DNA polymerase I for 4 hours at 15° C. (using an AMERSHAM kit). The tests of hybridization of the cDNA clones of the library were performed overnight under low stringency conditions, in a solution of a hybridization medium containing 5×SSC, 5×Denhart, 25% of formamide, 100 μg/ml of denatured salmon sperm DNA and the labelled probe (2×10⁷ cpm with a specificity of 10⁹ cpm/μg) at 37° C. The filters were subjected to three washing stages, successively in the presence of the three solutions whose compositions are stated as follows:

[0161] Washing n^(•) 1: 5×SSC, 0.1% SDS, at 25° C. for 4×15 minutes

[0162] Washing n^(•) 2: 2×SSC, 0.1% SDS, at 42° C. for 2×30 minutes

[0163] Washing n^(•) 3: 0.1×SSC, 0.1% SDS, at 65° C. for 2×30minutes

[0164] Each washing is followed by autoradiography of the filters.

[0165] Several positive clones were detected after washing n^(•) 1 and were still detected after washing n^(•) 2. However, all the signals disappeared after washing n^(•) 3. This indicates that the positive clones had only a weak relationship with the HIV-1 genome, which was nevertheless sufficient to perform the abovementioned selection. The positive clones were subcultured, redeposited on plaques and again hybridized with the same probe under the stringency conditions corresponding to washing n^(•) 1. Most of them were still positive.

[0166] The clones were also selected using a total human DNA probe under conditions of moderate stringency and by hybridization in 5×SSC, 5×Denhart and 40% formamide, followed by washing in 1×SSC, 0.1% SDS at 50° C. None of the previously positive clones was detected, and consequently did not correspond to specific repeated DNA or to the cDNA of the ribosomal RNA.

[0167] The positive M13 recombinant clones were cultured in a liquid medium and characterized as follows:

[0168] (1) Size of their Insertion:

[0169] An M13 single-stranded type DNA was obtained from each individual clone, and the synthesis of the second strand was performed with an M13 17-mer initiator sequence and the Klenow enzyme. The inserts were excised using EcoRI (BOEHRINGER) and analysed by agarose gel electrophoresis. The majority of the inserts contained from 200 to 600 and 200 bp, with the exception of the clone designated E2.1, which had an approximate length of 2 kbp.

[0170] (2) Analysis of the Nucleotide Sequence:

[0171] Several clones were partially sequenced using the dideoxy method of Sanger et al., described in Proc. Natl. Acad. Sci. 74:5463-7 (1977), which forms part of the present description. Various independent clones contained similar nucleotide sequences, with the exception of the poly(A) chains at their 3′ ends, the lengths of which were different. These results demonstrate that these cDNA clones were derived from the RNA template. Detailed sequence analysis of these cDNA clones, including the 3′ end of the HIV-2 genome, showed a limited relationship with HIV-1.

[0172] (3) Hybridization with the Genomic RNA and DNA of HIV-2:

[0173] (a) Production of the Genomic RNA of HIV-2:

[0174] An infected supernatant was centrifuged (50.000 revolutions, 30 minute.,). The pellet of the deposit was resuspended in 10 mM Tris pH 7.5, 1 mM EDTA, 0.1% SDS. One of the insertion clones, F1.1, was labelled and used as a probe for hybridization with the genomic RNA of different viral isolates, according to the “dot-blot” technique.

[0175] The “dot-blot” technique comprised the following stages:

[0176] (i) Depositing the sample (HIV-2 lysate) in spots on a nitrocellulose membrane soaked beforehand in 20×SSC (3 M NaCl, 0.3 M sodium citrate) and dried in the air, (ii) baking the membrane for 2 hours at 80° C., and (iii) performing the hybridization.

[0177] This hybridization was performed under high stringency conditions (5×SSC, 5×Denhart, 50% formamide at 42° C.). It was followed by washing in 0.1×SSC, 0.1% SDS at 65° C. Under these conditions, the probe hybridizes strongly to the spots originating from two independent isolates of HIV-2, including LAV-II ROD, from which the cloned cDNA originated. A weak hybridization signal was detected with the spot formed by STLV-III mac [Simian T-lymphotropic Virus (also known as “SIV”), type III macaque], and no hybridization was detected with the HIV-1 isolates.

[0178] The “Southern blot” experiments, employing the clone E2.1 containing the 2 kb insert as a ³²P-labelled probe, did not reveal any hybridization with the DNAs of uninfected cells, but detected bands in detached cells infected with HIV-2, under high stringency conditions. HIV-2 shows polymorphism at levels of its restriction map which are equivalent to those of the restriction maps of HIV-1. With the complete cellular DNA of infected cells, two types of signal arc detected by the “Southern blot” method:. (1) in DNA fractions having molecular weights MW of approximately 20 kb and more, in the case of integrated forms of the virus, and (2) in the fractions of lower MW (9,10 kb), in the case of the virus not integrated in the genome.

[0179] These characteristics are highly specific to a retrovirus.

[0180] Some experiments performed with STLV-III (SIV-3) from infected cells enabled it to be established that the simian retrovirus is relatively Distant from HIV-2 (the signal is detected exclusively under low stringency conditions). These experiments show that the abovementioned probes permit the specific detection of HIV-2.

[0181] (4) Subcloning of the cDNA of HIV-2 in a Bacterial Plasmid Vector:

[0182] The positive M13 clone, E 2.1, was selected and subcloned in a plasmid vector. The DNA of the recombinant M 13 (TG 130) phage E 2 was purified in the form of a single-stranded DNA (M-13-ROD-E2) containing the 2 kb insert containing the 3′ portion of the HIV-2 genome (obtained from HIV-2 ROD). This insert was transferred to plasmid pSP65, described by Melton, D. A., in 357 Nucleic Acid Res. 12:035-7056 (1984).

[0183] A second chain was constructed in vitro in the presence of the 17-mer initiator sequence (AMERSHAM), the four nucleotides A, C, T, G, and DNA polymerase I (Klenow). The EcoRI insert was excised by EcoRI digestion and purified on agarose gel, and then ligated to pSP65 which had itself been digested beforehand with EcoRI. The ligation mixture was used to transform E. coli strain DH1, and recombinants were selected on the basis of their capacity for resistance to ampicillin. The recombinants identified were cultured on LB medium (Luria medium) containing 50 μg/ml of ampilillin. These recombinant plasmids were purified and monitored for the presence of the correct inserted fragment.

[0184] One of the clones obtained, designated by the reference pSPE2, was deposited with the CNCM in Paris, France, under access n^(•) I-595 on Sep. 5, 1986.

[0185] The inserts derived from the cDNAs of HIV-2 and which were present inserted in the abovementioned probe contained the nucleotide sequence which has been defined above, in conformity with a part of E2.

Example II Cloning of a cDNA Complementary to the DNA Complementary to the Genomic RNA of HIV-2 Virions

[0186] HIV-2 virions were purified from 5 litres of a culture supernatant from a CEM line infected with a ROD isolate. A first strand of cDNA was synthesized in contact with sedimented purified virus, in the presence of an oligo(dT) initiator and employing an endogenous reaction activated by a detergent, according to the technique described by Alizon et al., Nature 312, 757-760 (1984). The RNA/cDNA hybrids were purified by extraction with a phenol/chloroform mixture and by precipitation with ethanol. The second strand of cDNA was produced in the presence of DNA polymerase I/RNAse H, according to the method described by Gubler and Hoffman ( ). The description in this paper is considered to be incorported herein by reference.

[0187] The double-stranded cDNA was provided with blunt ends in the presence of DNA polymerase T4, using the constituents of a cDNA synthesis kit marketed by AMERSHAM.

[0188] EcoRI adaptors (linker), marketed by PHARMACIA were attached to the end of the cDNA; the cDNA thereby modified was inserted, after digestion in the presence of EcoRI, into a dephosphorylated phage vector M13tg130 which was itself digested with EcoRI, also marketed by AMERSHAM. A cDNA band was obtained after transformation of E. coli strain TG1. Recombinant plaques (10⁴) were screened in situ on filters permitting replicas by hybridization with the clone J19 containing the 1.5 kb HindIII fragment mentioned above, originating from HIV-1.

[0189] The filters were prehybridized in the presence of a medium containing 5×SSC, 5×DENHARDT solution, 25% formaldehyde and denatured salmon sperm DNA (100 micro-grammes/ml), at 37° C. for 4 hours, and then hybridized for 16 hours in the same buffer (Tm -42° C.) in the presence of additional labelled probe (4×10⁷ cpm), to provide a final hybridization buffer solution containing 10⁶ cpm/ml.

[0190] Washing was carried out with a 5×SSC, 0.1% SDS solution at 25° C. for 2 hours (it being understood that 20×SSC corresponds to a 3 M NaCl and 0.3 M sodium citrate solution). The plaques which responded positively were purified and the M13 single-stranded DNAs were prepared and their ends sequenced according to the method of Sanger et al.

[0191] Hybridization of a DNA of Cells Infected with HIV-1 and HIV-2 and of RNAs of HIV1, HIV-2 and of SIV Virions, Respectively, with a Probe Derived from a Cloned cDNA of HIV-2.

[0192] The DNAs were extracted from infected CEM cells continuously producing HIV-1 and HIV-2, respectively. DNA samples of these two retroviruses, digested in some cases with 20 μg of PstI, and undigested in other cases, were subjected to electrophoresis on 0.8% agarose gel and transferred by the “Southern” method to a nylon membrane. Small volumes of infected supernatant, taken up in an NTE buffer containing 0.1% of SDS and having the same reverse transcriptase activity, were deposited on nitrocellulose which had been soaked beforehand in a 2×SSC solution.

[0193] A prehybridization was carried out in a solution containing 50% of formamide, 5×SSC, 5×Denhart and 100 mg/ml of denatured salmon sperm DNA, for 4 hours at 42° C. A hybridization was performed in the same buffer, to which 10% of dextran sulphate and 10⁶ cpm/ml of E2 labelled insert (specific activity 10⁹ cpm/μg) had been added, for 16 hours at 42° C. Two washings were then carried out with a 0.1×SSC, 0.1% SDS solution for 30 min each. After exposure for 16 hours to an intensifying screen, the Southern spot is dehybridized in 0.4 N NaOH, neutralized, and rehybridized under the same conditions with the HIV-1 probe labelled with 10⁹ cpm/μg.

Example III Cloning in Phage Lambda of the Complete DNA of the HIV-2 Provirus

[0194] The DNA of CEM cells infected with HIV-2 ROD (FIG. 2, bands a and c) is partially digested with Sau3AI. The 9-15 kb fraction was selected on a 5-40% sucrose gradient and ligated to the BamHI arm of the lambda L47.1 vector. The plaques (2×10⁶) obtained after in vitro packaging and deposition on E. coli strain LA 101 were screened in site by hybridization with the insert of the E2 cloned cDNA. Approximately 10 positive clones were purified on plaques and propagated in E. coli C600 recBC. The clones lambda ROE, 4, ROD 27 and ROD 35 were amplified, and their DNAs characterized by drawing up their restriction maps and by hybridization by Southern's method with the cDNA clone of HIV-2 under stringent conditions and with the gag-pol probes of HIV-1 under non-stringent conditions.

[0195]FIG. 8 shows schematically the structures of 3 of the recombinant phages obtained, ROD 4, ROD 27 and ROD 35.

[0196] The elongated rectangular portions of these diagrams correspond to proviral sequences originating from the DNAs of the initially infected CEM cells, the clear portions corresponding to retroviral sequences, the shaded portions to portions of cellular DNAs and the black portions to the LTR in the said viral sequences.

[0197] The thin lines designated by the letters L and R correspond to the arms originating from the Lambda L47.1 phage vector which was used for the cloning.

[0198] Some of the restriction sites have also been indicated: these are, more especially, the following sites: B BamHI; E: EcoRI; H: HindIII; K: KPnI; Ps: PstI; Pv: PvuII; S SagI X: XbaI.

[0199] These viral sequences have portions in common with the E2 sequence. The relative positions of these portions, determined by hybridization with E2, are also seen in the figures.

[0200] ROD 4 is derived from a circular viral DNA. ROD 27 and ROD 35 are derived from proviruses integrated in a cellular DNA structure.

[0201] Lastly, the inserts subcloned under the conditions described above, and their relative positions with respect to the corresponding ROD 4, ROD 27 and ROD 35 sequences, are shown in these figures.

[0202] These are, more especially, the inserts of plasmids pROD 27-5′, pROD 35-3′, pROD 4.6, pROD 4.8 and pROD 4.7.

[0203]FIG. 9 is a representation of the relative intensities of the hybridization spots which were produced between ROD-4 and sub-fragments 1 to 11 originating, respectively, from the different portions of a single-stranded DNA originating from an M13 subclone containing a nucleic acid derived from the whole LAV genome. The relative positions of these various fragments with respect to the whole LAV genome (determined by sequencing) are shown at the bottom of the figure. Point 12 corresponds to a control spot produced using a control DNA of the phage lambda.

[0204] The hybridization experiments in the spot transfer (dot blot) method were carried out under the low stringency conditions of Example II using, by way of a probe, the lambda ROD 4 recombinant containing the total cDNA of HIV-2. The washings were then carried out successively under the following conditions: 2×SSC, 0.1% SDS at 25° C. (Tm-42° C.), 1×SSC, 0.1% SDS at 60° C. (Tm-20° C.) and 0.1% ×SSC, 0.1% SDS at 60° C. (Tm-3° C.).

[0205] The spots shown were obtained after radiographic exposure overnight.

Example IV In Vitro Diagnostic Test for the Presence of HIV-2 Virus in a Biological Medium MATERIAL AND METHODS

[0206] Patients

[0207] HIV-2-infected patients were recruited among individuals visiting the Egas Moniz Hospital in Lisbon either for hospitalization or for consultation, between September 1985 and September 1986. For this selection, all individuals of African origin or having stayed in Africa underwent a serum, test for antibodies against both HIV-1 (Immunofluorescence-IFA- and/or ELISA) and HIV-2 (IFA). Only those patients who were proved serologically to be infected with HIV-2 were included in the study.

[0208] Virus Isolation

[0209] In 12 patients, HIV isolation was attempted as previously described. Briefly, the patient' peripheral blood lymphocytes (PBL) were stimulated with PHA, co-cultured with normal human PHA-stimulated PBLs and maintained in the presence of interleukin-2 (IL-2). Cultures were monitored for the presence of cytopathic effect (CPE) and for reverse transcriptase (RT) activity in the supernatant.

[0210] Immunofluorescence Assay (IFA)

[0211] IFA slides were prepared as follows: HIV-2-infected MOLT-4 cells were washed twice in PBS and layered onto IFA glass slides (10⁴ cells/well), air dried and fixed with cold acetone. For IFA these cells were reacted with a {fraction (1/10)} dilution of the test serum for 45 minutes at 37° C., washed, dried, and reacted with a fluorescein-conjugated goat antihuman IgG, A, M ({fraction (1/100)} diluted) for 30 minutes at 37° C. After washing, cells were counterstained in 0.006% Evans blue, mounted in 90% glycerol 10% PBS and examined under a fluorescence microscope.

[0212] Elisa

[0213] Some patients' sera were examined for antibodies to HIV-1 using the commercially available serum tests ELAVIA (Pasteur Diagnostics) or ABBOTT.

[0214] Radioimmunoprecipitation Assay (RIPA)

[0215] HIV-1 or HIV-2 infected CEM cells were cultured in the presence of 35_(S) cysteine (200 microCi/ml) for 16 hours. The supernatant was collected, viral particles were pelleted and lysed in RIPA buffer (Tris-HCL 50 mM pH 7.5, NaCl 150 mM, EDTA 1 mM, 1%. Triton ×100, sodium deoxycholate 0.1%, SDS 0.1%). For each reaction, 50 microlitres of a dilution of lysate corresponding to 10⁵ cpm was reacted with 5 microlitres of test serum for 18 hours at 4° C. Immune complexes were bound to Sepha-rose-protein A (PHARMACIA), washed, and eluted by boiling for 2 minutes. Eluted antigens were then analysed by SDS-polyacryl-amide gel electrophoresis and autoradiography.

[0216] Dot-Blot Hybridization

[0217] Virus isolated from patients' PBLs were pelleted and lysed in Tris-HCL 10 mM pH 7.5, NaCl 10 mM, EDTA 1 mM, SDS 0.5%. One microlitre of each lysate, corresponding to 50.000 cpm of RT activity, was deposited onto nitro-cellulose. Hybridization and washing wore conducted in high stringency conditions: hybridization in 6×SSC, 5×Denhart, 50% formamide, for 18 hours at 42° C.; and washing in 0.1×SSC, 0.1% SDS at 65° C. We used HIV-1 and HIV-2 probes, ³²P labelled to a specify activity of 10⁸ cpm/microgram. The HIV-1 probe corresponds to the complete genome of the LAV_(BRU) isolate, and HIV-2 probe was derived from a 2 kilobases cDNA clone from LAV-2_(ROD) isolate.

RESULTS

[0218] Patient Population

[0219] Thirty patients with serological and/or virologic evidence of HIV-2 infection were studied. They were 12 males and 18 females. The mean age was 35, ranging 11-55. All patients, except one, have stayed for several years in West Africa: 26 were born and living in Guinea-Bissau and 2 were originating from the Cape Verde Islands. One patient was an 11-year old boy from Angola who had lived in the Cape Verde islands for several years. The only European in the study population was a 40 year-old Portuguese man who had lived for 8 years in Zaïre, and denied any stay in West Africa.

[0220] Clinical Presentation

[0221] Among the 30 patients 17 had AIDS, according to the CDC criteria. The major symptom in these patients was chronic diarrhoea, together in most cases with a weight loss of more than 10 kilograms in a year. In 10 patients the diarrhoea was found to be associated with the presence of an intestinal opportunistic infection; in 7 cases the pathogen was Isospora belli alone, one patient had Cryptosporidium alone and 2 had both pathogens. In 3 cases no opportunistic intestinal pathogen was found. Among all 17 AIDS cases, oesophageal candidiasis was diagnosed in 8. Six AIDS patients had respiratory symptoms. Pulmonary tuberculosis was diagnosesφ in 2 and another unidentified mycobacterium was found in one. Two patients had pulmonary aspergillosis, one following a tuberculosis. Two other AIDS patients had recurrent episodes of pneumonitis with no pathogen identified, and one patient had Pneumocystis carinii pneumonia, which was only diagnosed post-moitem. Four of the 17 AIDS patients had Kaposi's sarcoma: in 3 cases it appeared limited to the skin, and in one patient postmortem examination revealed disseminated visceral lesions. Central nervous system disorders were found in 2 AIDS patients: one had cerebral lymphoma, and the other had subacute encephalitis of unknown cause.

[0222] Four patients were presenting with the symptoms of the AIDS-related complex (ARC): two had diffuse lymphadenopathy with persistent fever, one had chronic diarrhoea with weight loss, and one had recurrent episodes of bronchopneumonia and multiple lymphadenopathies.

[0223] Among the 9 remaining patients, 6 had no symptoms that could be considered as related to HIV infection, one had pulmonary tuberculosis alone, one had persistent diffuse lymphadenopathy alone, and one presented with neurologic syphillis. During the 12 months' period of the study 7 patients died, all presenting with AIDS.

[0224] Serological Studies

[0225] Each patient had at least one serum test for antibodies to booth HIV-1 and HIV-2. All patients' sera were tested by IFA for antibodies to HIV-2, and all were positive. Among them, 21 were also tested for antibodies to HIV-2 by RIPA: all clearly precipitated the high-molecular weight envelope glycoprotein of the virus, termed gp 140, and 16 of them also reacted with the major core protein p26, whereas only one reacted with another viral core protein, termed p16.

[0226] The sera were evaluated for the presence of cross-reacting antibodies to HIV-1 using different assays. An IFA test was used in 24 sera: 12 were negative, 10 were weakly reactive, and 2 were positive. In ELISA, 21 were tested: 16 were negative, and 5 were positive. Finally, 11 sera were tested for antibodies to HIV-1 proteins by RIPA. Three failed to react with any viral protein, 2 only precipitated the pol gene product p34, and 5 reacted with the major core protein p25. Two sera reacted only faintly with the envelope glycoprotein gp 110 of HIV-1. These two sera, and all sera with positive IFA or ELISA tests for antibodies to HIV-1, had a strong reactivity with the gp 140 of HIV-2 in RIPA, indicative of infection with HIV-2 rather than with HIV-1. Only one patient, that we did not include in the study population, was serologically found to be infected with HIV-1 and not with HIV-2. This patient was a 21-year-old woman from Central Africa (Sao Tome Islands) with AIDS.

[0227] Virus Isolation

[0228] Isolation of retroviruses from peripheral blood lymphocytes was attempted in 12 patients. HIV was isolated in 11, according to the presence of a typical cytopathic effect, and of a peak of particle-associated reverse transcriptase activity in the culture supernatants.

[0229] All 11 isolates were identified as HIV-2 using a dot-blot hybridization technique. Viral dots from 10 isolates were found to strongly hybridize in stringent conditions of hybridization and washing with a HIV-2 probe derived from a cloned HIV-2 cDNA, whereas none of them hybridized with a HIV-1 probe in the same conditions. One isolate only faintly hybridized with the HIV-2 probe, but it failed to hybridize with the HIV-1 probe.

[0230] Immunological Evaluation

[0231] Thirteen patients were evaluated for the number of circulating lymphocyte., identified as helper T cells (CD4+) and the ratio of helper:supressor T cells. Among these patients, 11 had AIDS: their mean absolute helper T cells count was 243+300/macrolitre and their mean helper:suppressor ratio was 0.25+0.15. One patient, clinically presenting with ARC, had a number of helper T lymphocytes of 240/microlitre and a ratio of 0.18. Another patient, with neurological syphillis and no evident HIV-related symptom, had a helper T lymphocyte count of 690/microlitre and a ratio of 0.82.

DISCUSSION

[0232] In this study, we demonstrated HIV-2 infection in 30 West African patients presenting either with AIDS, ARC or with no apparent HIV-related symptoms. The results nevertheless permit the conclussion that HIV-2 must be considered to be a major aetiological agent of AIDS in West African patients. The serological and virologic profiles that we observed indicate that HIV-2 infection was not often associated with HIV-1 infection in our patients. Despite important antigenic and genetic differences, HIV-1 and HIV-2 display similar tropism for CD4+ T lymphocytes, similar cytopathic effects, similar morphology, and share common immunoreactive epitopes in some of their constitutive proteins. Since all West African patients with HIV infection in this study were found to be infected with HIV-2 and none of them with HIV-1, the new virus HIV-2 may be the major cause of AIDS in West Africa.

[0233] The symptoms of HIV-2-related AIDS were not different from those of HIV-1 related AIDS in Central Africa: The most common symptom was chronic diarrhoea, with important weight loss mostly due to Isospora belli and/or Cryptosporidium. The frequency of other opportunistic infections, such as candidiasis, mycobacteria (including M. tuberculosis) and toxoplasmosis was found comparable to that in HIV-1-related African AIDS. Pneumocystis carinii pneumonia, a very common complication of AIDS in the USA and Europe, has only been found once in our study and cryptococcal meningitis was not detected.

[0234] Nevertheless, the immunological abnormalities found in HIV-2-infected AIDS patients are identical to those described in HIV-1-related AIDS.

[0235] Among the 30 patients, who all had serum antibodies reactive with HIV-2 antigens, only 7 had HIV-1 specific antibodies detectable using IFA or ELISA. In RIPA, all of these 7 patients had antibodies reactive with the other major core proteins p25 (HIV-1) or p26 (HIV-2), which share strongly immunoreactive epitopes. Five patients lacked such antibodies: all 5 had a negative HIV-1 ELISA. IFA was borderline in 3 and negative in 2. However, although some of them were not completely evaluated, we found 9 patients with serum antibodies to the viral core protein p26 of HIV-2 who had a weakly reactive or negative HIV-1 specific IFA and/or ELISA. These findings point to the importance of including HIV-2 antigens in the HIV serum tests used in Africa and perhaps in other areas.

[0236] A retrovirus was isolated from the peripheral lymphocytes of 11 patients. In all cases, viral growth was obtained within 2 weeks, characterized by the presence of reverse transcriptase activity in the culture supernatant and of cytopathic effect. However, this cytopathic effect appeared to vary in importance from one isolate to another: some isolates provided numerous large sized syncytia together with important cell lysis, whereas others exhibited only few syncytia of limited size, and affected poorly the viability of the culture.

[0237] RNA from all but one isolate was found to clearly hybridize in high stringency conditions with a prove derived from a HIV-2 cDNA clone, representing the 3′ end of the genome. None hybridized with a HIV-1 prove in the same conditions. This demonstrates that the isolates infecting these patients all belonged to the same type of virus. One isolate only poorly hybridized with HIV-1. This virus, however, was isolated from a patient with serum antibodies reacting with all the antigens of HIV-2 in RIPA.

[0238] This invention relates generally, in addition to HIV-2 virus its variants, to any equivalent virus which is infectious for man and possesses immunological characteristics specific to HIV-2. The invention relates generally to any virus which, in addition to the properties possessed by the HIV-2 viruses deposited with the CNCM, also possesses the characteristics which follow.

[0239] The preferred target for the HIV 2 retrovirus consists of human Leu 3 cells (or T4 lymphocytes) and and “immortalized” cells derived from these T4 lymphocytes, for example cells of the HUT 78 lines dealt with in the context of this patent application. In other words, it has a specific tropism for these cells. It can be cultured in permanent lines of the HUT, CEV, MOLT or similar type, Expressing the T4 protein. It is not infectious for T8 lymphocytes. It is cytotoxic for the human T4 lymphocytes. The cytopathogenic nature of HIV-2 viruses with respect to T4 lymphocytes manifests itself, in particular, by the appearance of multinucleated cells. It has a reverse transcriptase activity which requires the presence of Mg²⁺ ions and has a strong affinity for polyadenylate oligodeoxythymidylate (poly(A)-oligo(dT) 12-18). It has a density of approximately 1.16 in a sucrose gradient. It has a mean diameter of 140 nanometres and a core having a mean diameter of 41 nanometres. The lysates of this virus contain a p26 protein which does not cross immunologically with the p24 protein of HTLV-1 virus or HTLV-II virus. These p26 proteins hence have a molecular weight Which is slightly higher (by approximately 1000) than the corresponding p25 proteins of HIV-1 and slightly lower (again, of the order of approximately 1000 lower) than the corresponding p27 proteins of the SIV. The lysates of HIV-2 contain, in addition, a p16 protein which is not immunologically recognized by the p19 protein of HTLV-1 or of HTLV-II in RIPA (abbreviation for radioimmunoprecipitation assay) experiments. They contain, in addition, an envelope glycoprotein having a molecular weight of the order of 130,000-140,000, which does not cross immunologically with the gp 110 of HIV-1 but which, on the other hand, crosses immunologically with the gp 140 envelope glyco-protein of STLV-III. These lysates also contain proteins or glycoproteins which can be labelled with (³⁵S)cysteine, having molecular weights, respectively, of the order of 36,000 and 42,000-45,000. The genomic RNA of HIV-2 does not hybridize with the genomic RNA of HIV-1 under stringent conditions. Under non-stringent conditions, it does not hybridize with nucleotide sequence derived from HIV-1 and containing the env gene and the LTR adjacent to it. In particular, it does not hybridize with the nucleotide sequence 5290-9130 of HIV-1, nor with sequences of the pol region of the HIV-1 genome, in particular with the nucleotide sequence 2170-2240. under non-stringent conditions, it hybridizes weakly with nucleotide sequences of the HIV-1 region, in particular the nucleotide sequences 990-1070 and 990-1260.

[0240] It should be noted that any retrovirus which is infectious for man, capable of inducing one of the forms of AIDS, having the abovementioned essential properties and whose genomic RNA is capable of hibridizing under stringent conditions with those HIV-2 viral strains deposited with the CNCM (or with a cDNA or cDNA fragment derived from these genomic RNAs) is to be considered to be an equivalent of HIV-2.

[0241] The invention also relates to each of the antigens, in particular proteins and glycoproteins in the purified state, such as may be obtained from HIV-2. Reference to “purified” proteins or glycoproteins implies that these proteins or glycoproteins lead, respectively, only to single bands in polyacrylamide gel electrophoresis, in particular under the experimental conditions which have been described above. Any suitable method of separation and/or purification for obtaning each of these can be used. By way of example of a technique which can be employed, that describes by R. C. MONTELARO et al., J. of Virology, June 1982, pp. 1029-1038, will be mentioned.

[0242] The invention relates generally to all antigens, in particular proteins, glycoproteins or polypeptides, originating from an HIV-2 and having immunological properties equivalent to those of these antigenic compounds of HIV-2. Two antigens are said to be “equivalent”, in the context of this account, inasmuch as they are recognized by the same antibodies, in particular antibodies which can be isolated from a serum obtained from a patient who has been infected with an HIV-2, or inasmuch as they meet the conditions for “immunological equivalence” stated below.

[0243] Among equivalent polypeptides proteins or glycoproteins, there must be included fragments of the above antigens (or peptides reconstituted by chemical synthesis), inasmuch as they give rise to immunological cross-reactions with the antigens from which they are derived. In other words, the invention relates to any polypeptide which has, in common with abovementioned antigens, identical or similar epitopes capable of being recognized by the same antibodies. Belonging to this latter type of polypeptides are the products of expression of corresponding sequences of the DNAs which code for the corresponding polypeptide sequences.

[0244] The HIV-2 virus has proved to be usable as a source of antigens for detecting antibodies in all people who have come into contact with the HIV-2 virus.

[0245] The invention relates generally to any composition which can be used for the diagnosis of the presence in a biological fluid serum, in particular of people who have come into contact with HIV-2, of antibodies against at least one of the antigens of HIV-2. This composition can be applied to the selective diagnosis of the corresponding variety of AIDS, employing diagnostic techniques such as those described in the European patent application cited above, except that εχτβαψτσ, lysates or purified antigens of HIV-2 are used instead of those of HIV-1. In this connection, the invention relates more especially to compositions containing at least one of the proteins p12, p16, p26, which are the internal proteins, or p36 or gp 140. By way of examples of compositions, those which simultaneously contain the following will be mentioned.

[0246] p26 and gp 36

[0247] p26, p36 and gp 140,

[0248] p12, p16 and p26,

[0249] p16, p26 and gp 140, etc.

[0250] it is self-evident that these compositions signify only examples. In particular, the invention relates to the viral extracts or lysates containing this group of proteins and/or glycoproteins or all fractions from which one or more of the abovementioned proteins or glycoproteins has been separated beforehand.

[0251] The invention also relates to compositions containing a combination of proteins and/or glycoproteins of an HIV-2 with proteins and/or glycoproteins of an HIV-1, for example:

[0252] either core proteins of HIV-1 and HIV-2, in particular the p25 of an HIV-1 and p26 of an HIV-2, or alternatively the p18 of an HIV-1 and the p16 of an HIV-2,

[0253] or envelope glycoproteins of an HIV-1 and envelope glycoproteins of an HIV-2, in particular the gp 110 of HIV-1 and the gp 140 of HIV-2, or alternatively the p42 of HIV-1 and the p36 or p42-45 of HIV-2,

[0254] or, of course, mixtures of proteins and/or glycoproteins of an HIV-1 and proteins and/or glycoproteins of and HIV-2.

[0255] Such compositions, used for diagnosis, consequently make possible procedures for diagnosis of AIDS or of the symptoms which are associated with it, which extend over a wider spectrum of the aetiological agents responsible. It goes without saying that the use for diagnostic procedures of compositions which contain only proteins and/or glycoproteins of HIV-2 is nevertheless useful for more selective diagnosis of the category of retrovirus which can be held responsible for the disease.

[0256] The invention also relates to the DNAs or DNA fragments, more especially cloned DNAs and DNA fragments, obtained from the RNA and cDNAs derived from the RNA of the HIV-2 retrovirus. The invention also relates especially to all equivalent DNAs, in particular any DNA possessing sequence homologies with the DNA of HIV-2, especially with the sequences which code for the env and pol regions of the strain of HIV-2 deposited with the CNCM, equal at least to 50%, preferably to 70% and still more advantageously to 90%. It will also be stated generally that the invention relates to any equivalent DNA (or RNA) capable of hybridizing with the DNA or RNA of HIV-2 in the “spot blot” technique, under non-stringent conditions as defined above.

[0257] The invention likewise elates to the sera capable of being produced in animals by inoculating the latter with HIV-2. The invention hence relates more especially to the polyclonal antibodies directed more specifically against each of the antigens, in particular proteins or glycoproteins, of the virus. It also relates to the monoclonal antibodies which can be produced by traditional techniques, these monoclonal antibodies being directed, respectively, more specifically against the different proteins of HIV-2.

[0258] These polyclonal or monoclonal antibodies can be used in different applications. Their use for neutralizing the corresponding proteins, or even inhibiting the infectivity of the whole virus, will mainly be mentioned. They can also be used, for example, for demonstrating the viral antigens in biological preparations or for carrying out procedures for purification of the corresponding proteins and/or glycoproteins, for example by using them in affinity chromatography columns.

[0259] It is understood that, in general, the available technical literature (in particular that for which the bibliographic references are in the context of the present description) in respect of HIV-1 and the virus designated HTLV-III is to be considered to be incorporated herein by reference, inasmuch as the techniques described in this literature are applied under similar conditions to the isolation of HIV-2 virus or of the equivalent viruses, and to the production from these viruses of their different constituents (in particular proteins, glycoproteins, polypeptides and nucleid acids). Use can also be made of the teachings of this technical literature as regards the application of the different constituents in question, in particular to diagnostic procedures of the corresponding forms of LAS or AIDS.

[0260] The present invention relates more especially to a method for in vitro diagnosis of AIDS, which comprises bringing a serum or another biological medium originating from a patient who is the subject of the diagnosis into contact with a composition containing at least one of the proteins or glycoproteins of HIV-2, or alternatively an extract or lysate of the virus, and the detection of the immunological reaction. Examples of such compositions have been stated above.

[0261] Preferred methods involve, for example, immunoenzymatic reactions of the ELISA or immunofluorescence type. The titrations can be measurements by direct or indirect immunoflueorescence, by direct or indirect immunoenzymatic assays.

[0262] Thus, the present invention also relates to extracts of virus (either an extract of one or more HIV-2 viruses alone, or a mixture of extracts originating from one or more HIV-2 viruses, on the one hand, and one or more HIV-1 viruses, on the other hand), these extracts being labelled. Any suitable type of label can be used: enzymatic, fluorescent, radioactive and the like.

[0263] Such titrations comprise, for example:

[0264] the deposition of specified amounts of the extract or of the composition referred to according to the present invention in the wells of a microtitration plate;

[0265] introduction into these wells of increasing dilutions of serum principally containing the antibodies whose presence is to be detected in vitro;

[0266] the incubation of the microtitration plate;

[0267] careful washing of the microtitration plate with a suitable buffer;

[0268] the introduction into the wells of the microtitration plate of labeled antibodies specific for human immunoglobulins, the labelling being carried out with an enzyme chosen from those which are capable of hydrolysing a substrate in such a way that the latter then undergoes a modification of its absorption of radiation, at least in particular wavelength band, and

[0269] the detection, preferably in comparative fashion relative to a control, of the extent of hydrolysis of the substrate, as a measurement of the potential risks or of the effective presence of the disease.

[0270] The present invention also relates to outfits or kits for the above diagnosis, which comprise:

[0271] an extract or a more highly purified fraction of the types of virus stated above, this extract or fraction being labelled, for example radioactively, enzymatically or by immunofluorescence;

[0272] anti-(human immunoglobulins) or, a protein A (advantageously, bound to a support which is insoluble in water, such as agarose beads);

[0273] an extract of lymphocytes obtained from a person in good health;

[0274] buffers and, where appropriate, substrates for the visualization of the labelling.

[0275] It emerges from the foregoing that the invention relates to the diagnosis of HIV-2 virus, or of a variant, as a result of the use of the probes described above, in a method employing different stages recorded below, these stages being arranged specifically to bring out the characteristic properties of the HIV-2 virus.

[0276] The invention naturally also relates to the use of the cDNAs or their fragments (or recombinants containing them) as probes for the diagnosis of the presence or absence of HIV-2 virus in samples of serum or of other biological fluids or tissues obtained from patients suspected of being carriers of the HIV-2 virus. These probes are preferably also labelled (radioactive, enzymatic, fluorescent labels, and the like). Especially advantageous probes for carrying out the method for diagnosis of the HIV-2 virus, or of a variant of HIV-2, can be characterized in that they comprise all or a fraction of the cDNA complementary to the genome of the HIV-2 virus, or alternatively, in particular, the fragments present in the various clones identified above. There will be mentioned, more especially, a fraction of the cDNA of HIV-2 present in the clone E2, more especially the sequence of the 3′ end (LTR) and/or of the 5′ end of the HIV sequence of the abovementioned clone E2, or alternatively the cDNA containing the env region, of the cDNA of the HIV-2 virus.

[0277] The probes employed in this method for diagnosis of the HIV-2 virus and in the diagnostic kits are in no way limited to the probes described above. They comprise, on the contrary, all the nucleotide sequences originating from the genome of the HIV-2 virus, of a variant of HIV-2 or of a structurally related virus, inasmuch as they enable antibodies directed against an HIV-2 to be detected in biological fluids of people capable of developing one of the forms of AIDS. Naturally, the use of nucleotide sequences originating from an HIV-2 which is initially infectious for man in nevertheless preferred.

[0278] The detection can be carried out in all manners known per se, in particular by bringing these probes into contact either with the nucleic acids obtained from cells present in these sera or other biological media, for example cerebrospinal fluids, saliva, and the like, or with these media themselves in as much as their nucleic acids have been rendered accessible to hybridization with these probes, this being under conditions which permit hybridization between these probes and these nucleic acids, and by detection of the hybridization which may be produced. The abovementioned diagnosis, involving hybridization reactions, can also be carried out using mixtures of probes originating, respectively, from an HIV-1 and an HIV-2, insofar as it is unnecessary to differentiate between the type of HIV virus sought.

[0279] In general, the method for diagnosis of the presence or absence of the HIV-2 virus or a variant, in samples of sera or other fluids or tissues obtained from patients suspected of being carriers of the HIV-2 virus, comprises the following stages:

[0280] 1) the manufacture of a labelled probe,

[0281] 2) at least one hybridization stage performed under stringent conditions, by bringing the DNA of cells in the sample from the suspect patient into contact with the said labelled probe on a suitable membrane,

[0282] 3) washing of the said membrane with a solution which provides for the retention of these stringent conditions for the hybridization, and

[0283] 4) the detection of the presence or absence of the HIV-2 virus by an immunodetection method.

[0284] In another preferred embodiment of the method according to the invention, the abovementioned hybridization is performed under non-stringent conditions and the washing of the membrane is carried out under conditions adapted to those for the hybridization.

[0285] The invention relates in particular to HIV-2 viruses, characterized in that their viral RNA corresponds with a cDNA whose GAG and ENV genes comprise respectively the nucleotidic sequences which follow.

[0286] They result from the sequencing of corresponding regions of cDNA corresponding to the genome HIV-2 Rod. They are in correspondence with the aminoacids that they code. GAGRODN MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGlu ATGGGCGCGAGAAACTCCGTCTTGAGAGGGAAAAAAGCAGATGAA          .         .         .         . LeuGluArgIleArgLeuArgProGlyGlyLysLysLysTyrArg TTAGAAAGAATCAGGTTACGGCCCGGCGGAAAGAAAAAGTACAGG     .         .         .         .         . LeuLysHisIleValTrpAlaAlaAsnLysLeuAspArgPheGly CTAAAACATATTGTGTGGGCAGCGAATAAATTGGACAGATTCGGA        100         .         .         . LeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLysIle TTAGCAGAGAGCCTGTTGGAGTCAAAAGAGGGTTGTCAAAAAATT     .         .         .         .         . LeuThrValLeuAspProMetValProThrGlySerGluAsnLeu CTTACAGTTTTAGATCCAATGGTACCGACAGGTTCAGAAAATTTA          .       200         .         . LysSerLeuPheAsnThrValCysValIleTrpCysIleHisAla AAAAGTCTTTTTAATACTGTCTGCGTCATTTGGTGCATACACGCA     .         .         .         .         . GluGluLysValLysAspThrGluGlyAlaLysGlnIleValArg GAAGAGAAAGTGAAAGATACTGAAGGAGCAAAACAAATAGTGCGG          .         .       300         . ArgHisLeuValAlaGluThrGlyThrAlaGluLysMetProSer AGACATCTAGTGGCAGAAACAGGAACTGCAGAGAAAATGCCAAGC     .         .         .         .         . ThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyr ACAAGTAGACCAACAGCACCATCTAGCGAGAAGGGAGGAAATTAC          .         .         .       400 ProValGlnHisValGlyGlyAsnTyrThrHisIleProLeuSer CCAGTGCAACATGTAGGCGGCAACTACACCCATATACCGCTGAGT     .         .         .         .         . ProArgThrLeuAsnAlaTrpValLysLeuValGluGluLysLys CCCCGAACCCTAAATGCCTGGGTAAAATTAGTAGAGGAAAAAAAG          .         .         .         . PheGlyAlaGluValValProGlyPheGlnAlaLeuSerGluGly TTCGGGGCAGAAGTAGTGCCAGGATTTCAGGCACTCTCAGAAGGC   500         .         .         .         . CysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAsp TGCACGCCCTATGATATCAACCAAATGCTTAATTGTGTGGGCGAC          .         .         .         . HisGlnAlaAlaMetGlnIleIleArgGluIleIleAsnGluGlu CATCAAGCAGCCATGCAGATAATCAGGGAGATTATCAATGAGGAA     .       600         .         .         . AlaAlaGluTrpAspValGlnHisProIleProGlyProLeuPro GCAGCAGAATGGGATGTGCAACATCCAATACCAGGCCCCTTACCA          .         .         .         . AlaGlyGluLeuArgGluProArgGlySerAspIleAlaGlyThr GCGGGGCAGCTTAGAGAGCCAAGGGGATCTGACATAGCAGGGACA     .         .       700         .         . ThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGln ACAAGCACAGTAGAAGAACAGATCCAGTGGATGTTTAGGCCACAA AsnProValProValGlyAsnIleTyrArgArgTrpIleGlnIle AATCCTGTACCAGTAGGAAACATCTATAGAAGATGGATCCAGATA     .         .         .       800         . GlyLeuGlnLysCysValArgMetTyrAsnProThrAsnIleLeu GGATTGCAGAAGTGTGTCAGGATGTACAACCCGACCAACATCCTA          .         .         .         . AspIleLysGlnGlyProLysGluProPheGlnSerTyrValAsp GACATAAAACAGGGACCAAAGGAGCCGTTCCAAAGCTATGTAGAT     .         .         .         .       900 ArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaVal AGATTCTACAAAAGCTTGAGGGCAGAACAAACAGATCCAGCAGTG          .         .         .         . LysAsnTrpMetThrGlnThrLeuLeuValGlnAsnAlaAsnPro AAGAATTGGATGACCCAAACACTGCTAGTACAAAATGCCAACCCA     .         .         .         .         . AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu GACTGTAAATTAGTGCTAAAAGGACTAGGGATGAACCCTACCTTA       1000         .         .         . GluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGlyGln GAAGAGATGCTGACCGCCTGTCAGGGGGTAGGTGGGCCAGGCCAG     .         .         .         .         . LysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyPro AAAGCTAGATTAATGGCAGAGGCCCTGAAAGAGGTCATAGGACCT          .      1100         .         . AlaProIleProPheAlaAlaAlaGlnGlnArgLysAlaPheLys GCCCCTATCCCATTCGCAGCAGCCCAGCAGAGAAAGGCATTTAAA     .         .         .         .         . CysTrpAsnCysGlyLysGluGlyHisSerAlaArgGlnCysArg TGCTGGAACTGTGGAAAGGAAGGGCACTCGGCAAGACAATGCCGA          .         .      1200         . AlaProArgArgGlnGlyCysTrpLysCysGlyLysProGlyHis GCACCTAGAAGGCAGGGCTGCTGGAAGTGTGGTAAGCCAGGACAC     .         .         .         .         . IleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeu ATCATGACAAACTGCCCAGATAGACAGGCAGGTTTTTTAGGACTG          .         .         .      1300 GlyProTrpGlyLysLysProArgAsnPheProValAlaGlnVal GGCCCTTGGGGAAAGAAGCCCCGCAACTTCCCCGTGGCCCAAGTT     .         .         .         .         . ProGlnGlyLeuThrProThrAlaProProValAspProAlaVal CCGCAGGGGCTGACACCAACAGCACCCCCAGTGGATCCAGCAGTG          .         .         .         . AspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArgGlu GATCTACTGGAGAAATATATGCAGCAAGGGAAAAGACAGAGAGAG  1400         .         .         .         . GlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHis CAGAGAGAGAGACCATACAAGGAAGTGACAGAGGACTTACTGCAC          .         .         .         . LeuGluGlnGlyGluThrProTyrArgGluProProThrGluAsp CTCGAGCAGGGGGAGACACCATACAGGGAGCCACCAACAGAGGAC     .      1500         .         .         . LeuLeuHisLeuAsnSerLeuPheGlyLysAspGln TTGCTGCACCTCAATTCTCTCTTTGGAAAAGACCAG          .         .         . ENVRN MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAlaSerAlaCys ATGATGAATCAGCTGCTTATTGCCATTTTATTAGCTAGTGCTTGC          .         .         .         . LeuValTyrCysThrGlnTyrValThrValPheTyrGlyValPro TTAGTATATTGCACCCAATATGTAACTGTTTTCTATGGCGTACCC     .         .         .         .         . ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThrArgAsn ACGTGGAAAAATGCAACCATTCCCCTCTTTTGTGCAACCAGAAAT        100         .         .         . ArgAspThrTrpGlyThrIleGlnCysLeuProAspAsnAspAsp AGGGATACTTGGGGAACCATACAGTGCTTGCCTGACAATGATGAT     .         .         .         .         . TyrGlnGluIleThrLeuAsnValThrGluAlaPheAspAlaTrp TATCAGGAAATAACTTTGAATGTAACAGAGGCTTTTGATGCATGG          .       200         .         . AsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeu AATAATACAGTAACAGAACAAGCAATAGAAGATGTCTGGCATCTA     .         .         .         .         . PheGluThrSerIleLysProCysValLysLeuThrProLeuCys TTCGAGACATCAATAAAACCATGTGTCAAACTAACACCTTTATGT          .         .       300         . ValAlaMetLysCysSerSerThrGluSerSerThrGlyAsnAsn GTAGCAATGAAATGCAGCAGCACAGAGAGCAGCACAGGGAACAAC     .         .         .         .         . ThrThrSerLysSerThrSerThrThrThrThrThrProThrAsp ACAACCTCAAAGAGCACAAGCACAACCACAACCACACCCACAGAC          .         .         .       400 GlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAsp CAGGAGCAAGAGATAAGTGAGGATACTCCATGCGCACGCGCAGAC     .         .         .         .         . AsnCysSerGlyLeuGlyGluGluGluThrIleAsnCysGlnPhe AACTGCTCAGGATTGGGAGAGGAAGAAACGATCAATTGCCAGTTC          .         .         .         . AsnMetThrGlyLeuGluArgAspLysLysLysGlnTyrAsnGlu AATATGACAGGATTAGAAAGAGATAAGAAAAAACAGTATAATGAA   500         .         .         .         . ThrTrpTyrSerLysAspValValCysGluThrAsnAsnSerThr ACATGGTACTCAAAAGATGTGGTTTGTGAGACAAATAATAGCACA          .         .         .         . AsnGlnThrGlnCysTyrMetAsnHisCysAsnThrSerValIle AATCAGACCCAGTGTTACATGAACCATTGCAACACATCAGTCATC     .       600         .         .         . ThrGluSerCysAspLysHisTyrTrpAspAlaIleArgPheArg ACAGAATCATGTGACAAGCACTATTGGGATGCTATAAGGTTTAGA          .         .         .         . TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr TACTGTGCACCACCGGGTTATGCCCTATTAAGATGTAATGATACC     .         .       700         .         . AsnTyrSerGlyPheAlaProAsnCysSerLysValValAlaSer AATTATTCAGGCTTTGCACCCAACTGTTCTAAAGTAGTAGCTTCT          .         .         .         . ThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGly ACATGCACCAGGATGATGGAAACGCAAACTTCCACATGGTTTGGC     .         .         .       800         . PheAsnGlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHis TTTAATGGCACTAGAGCAGAGAATAGAACATATATCTATTGGCAT          .         .         .         . GlyArgAspAsnArgThrIleIleSerLeuAsnLysTyrTyrAsn GGCAGAGATAATAGAACTATCATCAGCTTAAACAAATATTATAAT     .         .         .         .       900 LeuSerLeuHisCysLysArgProGlyAsnLysThrValLysGln CTCAGTTTGCATTGTAAGAGGCCAGGGAATAAGACAGTGAAACAA          .         .         .         . IleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnPro ATAATGCTTATGTCAGGACATGTGTTTCACTCCCACTACCAGCCG     .         .         .         .         . IleAsnLysArgProArgGlnAlaTrpCysTrpPheLysGlyLys ATCAATAAAAGACCCAGACAAGCATGGTGCTGGTTCAAAGGCAAA       1000         .         .         . TrpLysAspAlaMetGlnGluValLysThrLeuAlaLysHisPro TGGAAAGACGCCATGCAGGAGGTGAAGACCCTTGCAAAACATCCC     .         .         .         .         . ArgTyrArgGlyThrAsnAspThrArgAsnIleSerPheAlaAla AGGTATAGAGGAACCAATGACACAAGGAATATTAGCTTTGCAGCG          .      1100         .         . ProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsn CCAGGAAAAGGCTCAGACCCAGAAGTAGCATACATGTGGACTAAC     .         .         .         .         . CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn TGCAGAGGAGAGTTTCTCTACTGCAACATGACTTGGTTCCTCAAT          .         .      1200         . TrpIleGluAsnLysThrHisArgAsnTyrAlaProCysHisIle TGGATAGAGAATAAGACACACCGCAATTATGCACCGTGCCATATA     .         .         .         .         . LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr AAGCAAATAATTAACACATGGCATAAGGTAGGGAGAAATGTATAT          .         .         .      1300 LeuProProArgGluGlyGluLeuSerCysAsnSerThrValThr TTGCCTCCCAGGGAAGGGGAGCTGTCCTGCAACTCAACAGTAACC     .         .         .         .         . SerIleIleAlaAsnIleAspTrpGlnAsnAsnAsnGlnThrAsn AGCATAATTGCTAACATTGACTGGCAAAACAATAATCAGACAAAC          .         .         .         . IleThrPheSerAlaGluValAlaGluLeuTyrArgLeuGluLeu ATTACCTTTAGTGCAGAGGTGGCAGAACTATACAGATTGGAGTTG  1400         .         .         .         . GlyAspTyrLysLeuValGluIleThrProIleGlyPheAlaPro GGAGATTATAAATTGGTAGAAATAACACCAATTGGCTTCGCACCT ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg ACAAAAGAAAAAAGATACTCCTCTGCTCACGGGAGACATACAAGA     .      1500         .         .         . GlyValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGly GGTGTGTTCGTGCTAGGGTTCTTGGGTTTTCTCGCAACAGCAGGT          .         .         .         . SerAlaMetGlyAlaArgAlaSerLeuThrValSerAlaGlnSer TCTGCAATGGGCGCTCGAGCGTCCCTGACCGTGTCGGCTCAGTCC     .         .      1600         .         . ArgThrLeuLeuAlaGlyIleValGlnGlnGlnGlnGlnLeuLeu CGGACTTTACTGGCCGGGATAGTGCAGCAACAGCAACAGCTGTTG          .         .         .         . AspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrp GACGTGGTCAAGAGACAACAAGAACTGTTGCGACTGACCGTCTGG     .         .         .      1700         . GlyThrLysAsnLeuGlnAlaArgValThrAlaIleGluLysTyr GGAACGAAAAACCTCCAGGCAAGAGTCACTGCTATAGAGAAGTAC          .         .         .         . LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg CTACAGGACCAGGCGCGGCTAAATTCATGGGGATGTGCGTTTAGA     .         .         .         .      1800 GlnValCysHisThrThrValProTrpValAsnAspSerLeuAla CAAGTCTGCCACACTACTGTACCATGGGTTAATGATTCCTTAGCA          .         .         .         . ProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnVal CCTGACTGGGACAATATGACGTGGCAGGAATGGGAAAAACAAGTC     .         .         .         .         . ArgTyrLeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGln CGCTACCTGGAGGCAAATATCAGTAAAAGTTTAGAACAGGCACAA       1900         .         .         . IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer ATTCAGCAAGAGAAAAATATGTATGAACTACAAAAATTAAATAGC     .         .         .         .         . TrpAspIlePheGlyAsnTrpPheAspLeuThrSerTrpValLys TGGGATATTTTTGGCAATTGGTTTGACTTAACCTCCTGGGTCAAG          .      2000         .         . TyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeu TATATTCAATATGGAGTGCTTATAATAGTAGCAGTAATAGCTTTA     .         .         .         .         . ArgIleValIleTyrValValGlnMetLeuSerArgLeuArgLys AGAATAGTGATATATGTAGTACAAATGTTAAGTAGGCTTAGAAAG          .         .      2100         . GlyTyrArgProValPheSerSerProProGlyTyrIleGlnGln GGCTATAGGCCTGTTTTCTCTTCCCCCCCCGGTTATATCCAACAG IleHisIleHisLysAspArgGlyGlnProAlaAsnGluGluThr ATCCATATCCACAAGGACCGGGGACAGCCAGCCAACGAAGAAACA          .         .         .      2200 GluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrp GAAGAAGACGGTGGAAGCAACGGTGGAGACAGATACTGGCCCTGG     .         .         .         .         . ProIleAlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeu GCGATAGCATATATACATTTCCTGATCCGCCAGCTGATTCGCCTC          .         .         .         . LeuThrArgLeuTyrSerIleCysArgAspLeuLeuSerArgSer TTGACCAGACTATACAGCATCTGCAGGGACTTACTATCCAGGAGC  2300         .         .         .         . PheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArgAspTrpLeu TTCCTGACCCTCCAACTCATCTACCAGAATCTCAGAGACTGGCTG          .         .         .         . ArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGln AGACTTAGAACAGCCTTCTTGCAATATGGGTGCGAGTGGATCCAA     .      2400         .         .         . GluAlaPheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAla GAAGCATTCCAGGCCGCCGCGAGGGCTACAAGAGAGACTCTTGCG          .         .         .         . GlyAlaCysArgGlyLeuTrpArgValLeuGluArgIleGlyArg GGCGCGTGCAGGGGCTTGTGGAGGGTATTGGAACGAATCGGGAGG     .         .      2500         .         . GlyIleLeuAlaValProArgArgIleArgGlnGlyAlaGluIle GGAATACTCGCGGTTCCAAGAAGGATCAGACAGGGAGCAGAAATC          .         .         .         . AlaLeuLeu***GlyThrAlaValSerAlaGlyArgLeuTyrGlu GCCCTCCTGTGAGGGACGGCAGTATCAGCAGGGAGACTTTATGAA     .         .         .      2600         . TyrSerMetGluGlyProSerSerArgLysGlyGluLysPheVal TACTCCATGGAAGGACCCAGCAGCAGAAAGGGAGAAAAATTTGTA          .         .         .         . GlnAlaThrLysTyrGly CAGGCAACAAAATATGGA     .         .

[0287] As already stated above, the invention naturally results to all HIV-2 viruses whose RNAs possess similar characteristics, particularly GAG and ENV regions which comprise sequences having nucleotidic sequence homologies of at least 50%, preferably 70%; and still more advantageously 90% with the corresponding GAG and ENV sequences of HIV-2 Rod.

[0288] The invention relates more particularly to the cDNA fragments which code, respectively, for the p16, p26 and p12 whose structures are also included in GAGRODN. In particular, it relates to the sequences extending:

[0289] from nucleotide 1 to nucleotide 405 (coding for p16);

[0290] from nucleotide 406 to nucleotide 1 155 (coding for p26); and

[0291] from nucleotide 1 156 to nucleotide 1 566 (coding for p12).

[0292] It also relates particularly to the cDNA fragment which codes for the gp140 included in ENVR and extending from the nucleotide 1 to the nucleotide 2 574.

[0293] The invention also relates to nucleotide sequences which distinguish from the preceding ones by nucleotide substitutions taking advantage of the degeneracy of the genetic code, as long as the substitutions do not involve a modification of the aminoacid sequences encoded by said nucleotide sequences.

[0294] Likewise the invention concerns proteins or glycoproteins whose aminoacid sequences correspond to those which are indicated in the preceding pages, as well as equivalent peptides, i. e. peptides which result from the preceding pages by addition, substitution or dilution of aminoacids which do not affect the overall immunological properties of said peptides.

[0295] The invention concerns especially the envelope glycoprotein which exhibits the aminoacid sequence encoded by ENVRN.

[0296] The invention also relates to an immunogenic composition characterized in that it comprises dosage units of envelope antigen, particularly the gp140 of the HIV-2 virus, such as to enable the administration of dosage units from 10 to 500, particularly from 50 to 100 mg/kg of body weight.

[0297] Finally the invention concerns a process for producing any of the above indicated proteins (p12, p16 or p26) or of the protein having the structure of gp140, or of any determined part of said proteins, which process comprises inserting the corresponding nucleic acid sequence in a vector capable of transforming a suitably chosen cellular host and to permit the expression of an insert contained in said vector, transforming said chosen host by said vector which contains said nucleic sequence, culturing the cellular host transformed by said modified vector, recovering and purifying the protein expressed.

[0298] The techniques disclosed in European patent application 85 905513.9 filed on Oct. 18, 1985 for the production of peptides or proteins consisting of expression products of nucleic acid sequences derived of the genome of HIV-1 are also applicable to the production of the above said peptides or proteins derived of HIV-2. The description of this European application is incorporated herein by reference, particularly as concerns the techniques.

[0299] As an indication, molecular weights (MP) of HIV-2 proteins are given in comparison with those of HIV-1. MP of HIV-2 proteins MP of HIV-1 proteins kd kd entire gag 58.3 entire gag 55.8 p 16 15 p 18 14.9 p 26 27.6 p 12 15.8 env 98.6 env 97.4 external env 57.4 Transmembrane env 41.2

[0300] HIV-2 Mir and HIV-2ROD have also been deposited in the “National Collection of Animal Cell Cultures” (ECACC) in Salisbury (Great-Britain) on Jan. 9, 1987, under accessing numbers 87 011001 and 87 011002 respectively.

[0301] Moreover, plasmids pROD35 and pROD27.5 have been deposited at the “National Collection of Industrial Bacteria” (NCIB) in Aberdeen (Great-Britain) on Jan. 9, 1987 under accessing numbers 12 398 and 12 399 respectively.

[0302] All the publications which are referred to in the present disclosure are incorporated herein by reference.

BIBLIOGRAPHIE

[0303] 1—F. Barré-Sinoussi et al., Science 220, 868 (1983).

[0304] 2—L. Montagnier et al., In: Human Tcell leukemia Orlymphoma viruses (Gallo, R. C., Essex, M. E., Gross, L., eds.) Cold Spring Harbor Laboratory, New York, 363 (1984).

[0305] 3—M. Popovic, M. G. Sarngadharan, E. Read, R. C. Gallo, Science 224, 497 (1984).

[0306] 4—J. Levy et al., Science 225, 840 (1984).

[0307] 5—P. Sonigo et al., Cell 42, 369 (1985).

[0308] 7—J. W. Curran et al., Science 229, 1352 (1985).

[0309] 8—A. Ellrodt et al., Lancet i, 1383 (1984).

[0310] 9—P. Piot et al., Lancet ii, 65 (1984).

[0311] 10—F. Brun-Vezinet et al., Science 226, 453 (1984).

[0312] 11—N. Clumeck et al., N. Engl. J. Med. 313, 182 (1985).

[0313] 12—A. B. Rabson and M. A. Martin, Cell 40, 477 (1985).

[0314] 13—S. Benn et al., Science 230, 949 (1985).

[0315] 14—M. Alizon, Manuscript in preparation.

[0316] 15—F. Brun-Vezinet, Unpublished data.

[0317] 16—M. D. Daniel et al., Science 228, 1201 (1985).

[0318] 17—P. J. Kanki et al., Science 228, 1199 (1985).

[0319] 18—N. L. Letwin et al., Science 230, 71 (1985).

[0320] 19—A. Gatzar et al., Blood 55, 409 (1980).

[0321] 20—D. Klatzmann et al., Science 225, 59 (1984).

[0322] 21—L. Montagnier et al., Virology 144, 283 (1985).

[0323] 22—J. S. Allan et al., Science 228, 1091 (1985).

[0324] 23—F. CHIVel, Manuscript in preparation.

[0325] 24—F. diMarzo Veronese et al., Science 229, 1402 (1985).

[0326] 25—V. S. Kalyanaraman et al., Science 218, 571 (1982).

[0327] 26—I. S. Y. Chen, J. McLaughlin, J. C. Gasson, S. C. Clark and D. W. Golde, Nature 305, 502 (1983).

[0328] 27—F. Barin et al., Lancet ii, 1387 (1985).

[0329] 28—P. J. Kanki, J. Alroy, M. Essex, Science 230, 951 (1985).

[0330] 29—H. Towbin et al., Proc. Natl. Acad. Sci. USA 76, 4350 (1979).

[0331] 30—S. Wain-Hobson, P. Sonigo, O. Danos, S. Cole et M. Alizon, Cell 40, 9 (1985).

[0332] 31—M. Alizon et al., Nature 312, 757 (1984). 

1. HIV-2 retrovirus or variance of this virus, which retrovirus has infectious properties with respect to human T4 lymphocytes and the essential morphological and immunological properties of any of the retroviruses deposited at the CNCM under n^(•) I-502, I-532, I-642 and I-643:
 2. The purified retrovirus of claim 1 which possesses the following properties: the preferred target for the HIV-2 retrovirus consists of human Leu 3 cells (or T4 lymphocytes) and for permanent cell lines derived of said T4 lymphocytes; it is cytotoxic for the human T4 lymphocytes which it infects; it has a reverse transcriptase activity which requires the presence of Mg²⁺ ions and has a strong affinity for poly adenylate oligodeoxythymidylate (poly(A)-oligo(dT) 12-18); it has a density of approximately 1.16 in a sucrose gradient; it has a mean diameter of 140 nanometres and a core having mean diameter of 41 nanometres; it can be cultivated in permanent cell lines expressing the T4 protein; it is not infectious in T8 lymphocytes; the lysates of this virus contain p26 protein which does not crossreact immunologically with p24 protein of the HTLV-1 virus or of the HTLV-2; said lysates further contain p-16 protein which is not recognized immunologically by p19 protein of HTLV-1 or of HTLV-2 in radioimmunoprecipitation assays; said lysates further contain an envelope glycoprotein having a molecular weight of the order of 130,000-140,000 which does not crossreact immunologically with gp110 of HTLV-1 retrovirus; said lysates further contain a molecule which can be labelled by ³⁵S-cystein, having an apparent molecular weight of about 36,000; the genomic RNA of HIV-2 hybridizes neither with the genomic RNA, nor with the ENV gene, nor with the LTRs of HIV-1 under stringent conditions; the genomic RNA of HIV-2 hybridizes weakly under non-stringent conditions with nucleotide sequences of the CAG region of the HIV-1 genome.
 3. The retrovirus of claim 2 whose lysates also contain a molecule having an apparent molecular weight of 42,000-45,000.
 4. The retrovirus of any of claims 1 to 3, wherein the nucleotidic sequence of its genomic RNA which comprises the R region and the U3 region also comprises a nucleotidic sequence which corresponds with the following nucleotide sequence: GTGGAAGGCGAGACTGAAAGCAAGAGGAATACCATTTAGTTAAAGGACAG GAACAGCTATACTTGGTCAGGGCAGGAAGTAACTAACAGAAACAGCTGAG ACTGCAGGGACTTTCCAGAAGGGGCTGTAACCAAGGGAGGGACATGGGAG GAGCTGGTGGGGAACGCCTCATATTCTCTGTATAATATACCCGCTGCTTG CATTGTACTTCAGTCGCTCTGCGGAGAGGCTGGCAGATTGAGCCCTGGAG GATCTCTCCAGCACTAGACGGATGAGCCTGGGTGCCCTGCTAGACTCTCA CCAGCACTTGGCCGGTGCTGGCAGACGGCCCCACGCTTGCCTGCTTAAAA ACCTTCCTTAATAAAGCTGCAGTAGAAGCA


5. The retrovirus of anyone of claims 1 to 4 whose genomic RNA also contains a GAG sequence which corresponds with the following nucleotide sequence: GAGRODN ATGGGCGCGAGAAACTCCGTCTTGAGAGGGAAAAAAGCAGATGAA          .         .         .         . TTAGAAAGAATCAGGTTACGGCCCGGCGGAAAGAAAAAGTACAGG     .         .         .         .         . CTAAAACATATTGTGTGGGCAGCGAATAAATTGGACAGATTCGGA        100         .         .         . TTAGCAGAGAGCCTGTTGGAGTCAAAAGAGGGTTGTCAAAAAATT     .         .         .         .         . CTTACAGTTTTAGATCCAATGGTACCGACAGGTTCAGAAAATTTA          .       200         .         . AAAAGTCTTTTTAATACTGTCTGCGTCATTTGGTGCATACACGCA     .         .         .         .         . GAAGAGAAAGTGAAAGATACTGAAGGAGCAAAACAAATAGTGCGG          .         .       300         . AGACATCTAGTGGCAGAAACAGGAACTGCAGAGAAAATGCCAAGC     .         .         .         .         . ACAAGTAGACCAACAGCACCATCTAGCGAGAAGGGAGGAAATTAC          .         .         .       400 CCAGTGCAACATGTAGGCGGCAACTACACCCATATACCGCTGAGT     .         .         .         .         . CCCCGAACCCTAAATGCCTGGGTAAAATTAGTAGAGGAAAAAAAG          .         .         .         . TTCGGGGCAGAAGTAGTGCCAGGATTTCAGGCACTCTCAGAAGGC   500         .         .         .         . TGCACGCCCTATGATATCAACCAAATGCTTAATTGTGTGGGCGAC          .         .         .         . CATCAAGCAGCCATGCAGATAATCAGGGAGATTATCAATGAGGAA     .       600         .         .         . GCAGCAGAATGGGATGTGCAACATCCAATACCAGGCCCCTTACCA          .         .         .         . GCGGGGCAGCTTAGAGAGCCAAGGGGATCTGACATAGCAGGGACA     .         .       700         .         . ACAAGCACAGTAGAAGAACAGATCCAGTGGATGTTTAGGCCACAA AATCCTGTACCAGTAGGAAACATCTATAGAAGATGGATCCAGATA     .         .         .       800         . GGATTGCAGAAGTGTGTCAGGATGTACAACCCGACCAACATCCTA          .         .         .         . GACATAAAACAGGGACCAAAGGAGCCGTTCCAAAGCTATGTAGAT     .         .         .         .       900 AGATTCTACAAAAGCTTGAGGGCAGAACAAACAGATCCAGCAGTG          .         .         .         . AAGAATTGGATGACCCAAACACTGCTAGTACAAAATGCCAACCCA     .         .         .         .         . GACTGTAAATTAGTGCTAAAAGGACTAGGGATGAACCCTACCTTA       1000         .         .         . GAAGAGATGCTGACCGCCTGTCAGGGGGTAGGTGGGCCAGGCCAG     .         .         .         .         . AAAGCTAGATTAATGGCAGAGGCCCTGAAAGAGGTCATAGGACCT          .      1100         .         . GCCCCTATCCCATTCGCAGCAGCCCAGCAGAGAAAGGCATTTAAA     .         .         .         .         . TGCTGGAACTGTGGAAAGGAAGGGCACTCGGCAAGACAATGCCGA          .         .      1200         . GCACCTAGAAGGCAGGGCTGCTGGAAGTGTGGTAAGCCAGGACAC     .         .         .         .         . ATCATGACAAACTGCCCAGATAGACAGGCAGGTTTTTTAGGACTG          .         .         .      1300 GGCCCTTGGGGAAAGAAGCCCCGCAACTTCCCCGTGGCCCAAGTT     .         .         .         .         . CCGCAGGGGCTGACACCAACAGCACCCCCAGTGGATCCAGCAGTG          .         .         .         . GATCTACTGGAGAAATATATGCAGCAAGGGAAAAGACAGAGAGAG  1400         .         .         .         . CAGAGAGAGAGACCATACAAGGAAGTGACAGAGGACTTACTGCAC          .         .         .         . CTCGAGCAGGGGGAGACACCATACAGGGAGCCACCAACAGAGGAG     .      1500         .         .         . TTGCTGCACCTCAATTCTCTCTTTGGAAAAGACCAG          .         .         .


6. The retrovirus of anyone of claims 1 to 5 whose genomic RNA contains an ENV sequence which corresponds with the following nucleotide sequence: ENVRN ATGATGAATCAGCTGCTTATTGCCATTTTATTAGCTAGTGCTTGC          .         .         .         . TTAGTATATTGCACCCAATATGTAACTGTTTTCTATGGCGTACCC     .         .         .         .         . ACGTGGAAAAATGCAACCATTCCCCTCTTTTGTGCAACCAGAAAT        100         .         .         . AGGGATACTTGGGGAACCATACAGTGCTTGCCTGACAATGATGAT     .         .         .         .         . TATCAGGAAATAACTTTGAATGTAACAGAGGCTTTTGATGCATGG          .       200         .         . AATAATACAGTAACAGAACAAGCAATAGAAGATGTCTGGCATCTA     .         .         .         .         . TTCGAGACATCAATAAAACCATGTGTCAAACTAACACCTTTATGT          .         .       300         . GTAGCAATGAAATGCAGCAGCACAGAGAGCAGCACAGGGAACAAC     .         .         .         .         . ACAACCTCAAAGAGCACAAGCACAACCACAACCACACCCACAGAC          .         .         .       400 CAGGAGCAAGAGATAAGTGAGGATACTCCATGCGCACGCGCAGAC     .         .         .         .         . AACTGCTCAGGATTGGGAGAGGAAGAAACGATCAATTGCCAGTTC          .         .         .         . AATATGACAGGATTAGAAAGAGATAAGAAAAAACAGTATAATGAA   500         .         .         .         . ACATGGTACTCAAAAGATGTGGTTTGTGAGACAAATAATAGCACA          .         .         .         . AATCAGACCCAGTGTTACATGAACCATTGCAACACATCAGTCATC     .       600         .         .         . ACAGAATCATGTGACAAGCACTATTGGGATGCTATAAGGTTTAGA          .         .         .         . TACTGTGCACCACCGGGTTATGCCCTATTAAGATGTAATGATACC     .         .       700         .         . AATTATTCAGGCTTTGCACCCAACTGTTCTAAAGTAGTAGCTTCT          .         .         .         . ACATGCACCAGGATGATGGAAACGCAAACTTCCACATGGTTTGGC     .         .         .       800         . TTTAATGGCACTAGAGCAGAGAATAGAACATATATCTATTGGCAT          .         .         .         . GGCAGAGATAATAGAACTATCATCAGCTTAAACAAATATTATAAT     .         .         .         .       900 CTCAGTTTGCATTGTAAGAGGCCAGGGAATAAGACAGTGAAACAA          .         .         .         . ATAATGCTTATGTCAGGACATGTGTTTCACTCCCACTACCAGCCG     .         .         .         .         . ATCAATAAAAGACCCAGACAAGCATGGTGCTGGTTCAAAGGCAAA       1000         .         .         . TGGAAAGACGCCATGCAGGAGGTGAAGACCCTTGCAAAACATCCC     .         .         .         .         . AGGTATAGAGGAACCAATGACACAAGGAATATTAGCTTTGCAGCG          .      1100         .         . CCAGGAAAAGGCTCAGACCCAGAAGTAGCATACATGTGGACTAAC     .         .         .         .         . TGCAGAGGAGAGTTTCTCTACTGCAACATGACTTGGTTCCTCAAT          .         .      1200         . TGGATAGAGAATAAGACACACCGCAATTATGCACCGTGCCATATA     .         .         .         .         . AAGCAAATAATTAACACATGGCATAAGGTAGGGAGAAATGTATAT          .         .         .      1300 TTGCCTCCCAGGGAAGGGGAGCTGTCCTGCAACTCAACAGTAACC     .         .         .         .         . AGCATAATTGCTAACATTGACTGGCAAAACAATAATCAGACAAAC          .         .         .         . ATTACCTTTAGTGCAGAGGTGGCAGAACTATACAGATTGGAGTTG  1400         .         .         .         . GGAGATTATAAATTGGTAGAAATAACACCAATTGGCTTCGCACCT          .         .         .         . ACAAAAGAAAAAAGATACTCCTCTGCTCACGGGAGACATACAAGA     .      1500         .         .         . GGTGTGTTCGTGCTAGGGTTCTTGGGTTTTCTCGCAACAGCAGGT          .         .         .         . TCTGCAATGGGCGCTCGAGCGTCCCTGACCGTGTCGGCTCAGTCC     .         .      1600         .         . CGGACTTTACTGGCCGGGATAGTGCAGCAACAGCAACAGCTGTTG          .         .         .         . GACGTGGTCAAGAGACAACAAGAACTGTTGCGACTGACCGTCTGG     .         .         .      1700         . GGAACGAAAAACCTCCAGGCAAGAGTCACTGCTATAGAGAAGTAC          .         .         .         . CTACAGGACCAGGCGCGGCTAAATTCATGGGGATGTGCGTTTAGA     .         .         .         .      1800 CAAGTCTGCCACACTACTGTACCATGGGTTAATGATTCCTTAGCA          .         .         .         . CCTGACTGGGACAATATGACGTGGCAGGAATGGGAAAAACAAGTC     .         .         .         .         . CGCTACCTGGAGGCAAATATCAGTAAAAGTTTAGAACAGGCACAA       1900         .         .         . ATTCAGCAAGAGAAAAATATGTATGAACTACAAAAATTAAATAGC     .         .         .         .         . TGGGATATTTTTGGCAATTGGTTTGACTTAACCTCCTGGGTCAAG          .      2000         .         . TATATTCAATATGGAGTGCTTATAATAGTAGCAGTAATAGCTTTA     .         .         .         .         . AGAATAGTGATATATGTAGTACAAATGTTAAGTAGGCTTAGAAAG          .         .      2100         . GGCTATAGGCCTGTTTTCTCTTCCCCCCCCGGTTATATCCAACAG ATCCATATCCACAAGGACCGGGGACAGCCAGCCAACGAAGAAACA          .         .         .      2200 GAAGAAGACGGTGGAAGCAACGGTGGAGACAGATACTGGCCCTGG     .         .         .         .         . GCGATAGCATATATACATTTCCTGATCCGCCAGCTGATTCGCCTC          .         .         .         . TTGACCAGACTATACAGCATCTGCAGGGACTTACTATCCAGGAGC  2300         .         .         .         . TTCCTGACCCTCCAACTCATCTACCAGAATCTCAGAGACTGGCTG          .         .         .         . AGACTTAGAACAGCCTTCTTGCAATATGGGTGCGAGTGGATCCAA     .      2400         .         .         . GAAGCATTCCAGGCCGCCGCGAGGGCTACAAGAGAGACTCTTGCG          .         .         .         . GGCGCGTGCAGGGGCTTGTGGAGGGTATTGGAACGAATCGGGAGG     .         .      2500         .         . GGAATACTCGCGGTTCCAAGAAGGATCAGACAGGGAGCAGAAATC          .         .         .         . GCCCTCCTGTGAGGGACGGCAGTATCAGCAGGGAGACTTTATGAA     .         .         .      2600         . TACTCCATGGAAGGACCCAGCAGCAGAAAGGGAGAAAAATTTGTA          .         .         .         . CAGGCAACAAAATATGGA     .         .


7. The retrovirus of anyone of claims 1 to 6 whose RNA virtually hybridizes neither with the ENV gene and the LTR close to it, particularly with the nucleotide sequence 5290-9130 of HIV-1, nor with the sequences of the POL region of the HIV-1 genome, particularly with the nucleotide sequence 2170-2240 of HIV-1.
 8. A composition comprising at least one antigen, particularly a protein or glycoprotein of HIV-2 virus according to anyone of claims 1 to
 7. 9. The composition of claim 8 which consists of total extract or lysate of said retrovirus.
 10. The composition of claim 8 wherein said antigen consists of at least one of the internal core proteins of said virus, particularly p12, p16 and p26, which have apparent molecular weight of the order of 12,000, 16,000 and 26,000.
 11. The composition of claim 8, characterized in that it contains a gp140 glycoprotein having an apparent molecular weight of about 130,000-140,000.
 12. An antigen which provides a single bound in electrophoresis on a polyacrylamid gel which comprises, in common with one of the purified antigens of HIV-2 retrovirus, an epitope that is recognized by the serum of a carrier of antibody against HIV-2.
 13. A purified antigen having the immunological characteristics of one of the following proteins or glycoproteins of HIV-2: p12, p16, p26, p36, p42 and gp140.
 14. An antigen of claim 13 which has the following aminoacid sequence or a part of said sequence recognized by anti-p12 antibodies:                               ArgLysAlaPheLys                                   .         . CysTrpAsnCysGlyLysGluGlyHisSerAlaArgGlnCysArg          .         .      1200         . AlaProArgArgGlnGlyCysTrpLysCysGlyLysProGlyHis     .         .         .         .         . IleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeu          .         .         .      1300 GlyProTrpGlyLysLysProArgAsnPheProValAlaGlnVal     .         .         .         .         . ProGlnGlyLeuThrProThrAlaProProValAspProAlaVal          .         .         .         . AspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArgGlu  1400         .         .         .         . GlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHis          .         .         .         . LeuGluGlnGlyGluThrProTyrArgGluProProThrGluAsp     .      1500         .         .         . LeuLeuHisLeuAsnSerLeuPheGlyLysAspGln          .         .         .


15. An antigen of claim 13 which has the following aminoacid sequence or a part of said sequence recognized by anti-p16 antibodies: MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGlu          .         .         .         . LeuGluArgIleArgLeuArgProGlyGlyLysLysLysTyrArg     .         .         .         .         . LeuLysHisIleValTrpAlaAlaAsnLysLeuAspArgPheGly        100         .         .         . LeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLysIle     .         .         .         .         . LeuThrValLeuAspProMetValProThrGlySerGluAsnLeu          .       200         .         . LysSerLeuPheAsnThrValCysValIleTrpCysIleHisAla     .         .         .         .         . GluGluLysValLysAspThrGluGlyAlaLysGlnIleValArg          .         .       300         . ArgHisLeuValAlaGluThrGlyThrAlaGluLysMetProSer     .         .         .         .         . ThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyr          .         .         .       400


16. An antigen of claim 13 which has the following aminoacid sequence or a part of said sequence recognized by anti-p26 antibodies: ProValGlnHisValGlyGlyAsnTyrThrHisIleProLeuSer     .         .         .         .         . ProArgThrLeuAsnAlaTrpValLysLeuValGluGluLysLys          .         .         .         . PheGlyAlaGluValValProGlyPheGlnAlaLeuSerGluGly   500         .         .         .         . CysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAsp          .         .         .         . HisGlnAlaAlaMetGlnIleIleArgGluIleIleAsnGluGlu     .       600         .         .         . AlaAlaGluTrpAspValGlnHisProIleProGlyProLeuPro          .         .         .         . AlaGlyGlnLeuArgGluProArgGlySerAspIleAlaGlyThr     .         .       700         .         . ThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGln AsnProValProValGlyAsnIleTyrArgArgTrpIleGlnIle     .         .         .       800         . GlyLeuGlnLysCysValArgMetTyrAsnProThrAsnIleLeu          .         .         .         . AspIleLysGlnGlyProLysGluProPheGlnSerTyrValAsp     .         .         .         .       900 ArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaVal          .         .         .         . LysAsnTrpMetThrGlnThrLeuLeuValGlnAsnAlaAsnPro     .         .         .         .         . AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu       1000         .         .         . GluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGlyGln     .         .         .         .         . LysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyPro          .      1100         .         . AlaProIleProPheAlaAlaAlaGlnGln


17. An antigen of claim 13 which has the following aminoacid sequence or a part of said sequence recognized by anti-gp140 antibodies: ENVRN MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAlaSerAlaCys          .         .         .         . LeuValTyrCysThrGlnTyrValThrValPheTyrGlyValPro     .         .         .         .         . ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThrArgAsn        100         .         .         . ArgAspThrTrpGlyThrIleGlnCysLeuProAspAsnAspAsp     .         .         .         .         . TyrGlnGluIleThrLeuAsnValThrGluAlaPheAspAlaTrp          .       200         .         . AsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeu     .         .         .         .         . PheGluThrSerIleLysProCysValLysLeuThrProLeuCys          .         .       300         . ValAlaMetLysCysSerSerThrGluSerSerThrGlyAsnAsn     .         .         .         .         . ThrThrSerLysSerThrSerThrThrThrThrThrProThrAsp          .         .         .       400 GlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAsp     .         .         .         .         . AsnCysSerGlyLeuGlyGluGluGluThrIleAsnCysGlnPhe          .         .         .         . AsnMetThrGlyLeuGluArgAspLysLysLysGlnTyrAsnGlu   500         .         .         .         . ThrTrpTyrSerLysAspValValCysGluThrAsnAsnSerThr          .         .         .         . AsnGlnThrGlnCysTyrMetAsnHisCysAsnThrSerValIle     .       600         .         .         . ThrGluSerCysAspLysHisTyrTrpAspAlaIleArgPheArg          .         .         .         . TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr     .         .       700         .         . AsnTyrSerGlyPheAlaProAsnCysSerLysValValAlaSer          .         .         .         . ThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGly     .         .         .       800         . PheAsnGlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHis          .         .         .         . GlyArgAspAsnArgThrIleIleSerLeuAsnLysTyrTyrAsn     .         .         .         .       900 LeuSerLeuHisCysLysArgProGlyAsnLysThrValLysGln          .         .         .         . IleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnPro     .         .         .         .         . IleAsnLysArgProArgGlnAlaTrpCysTrpPheLysGlyLys       1000         .         .         . TrpLysAspAlaMetGlnGluValLysThrLeuAlaLysHisPro     .         .         .         .         . ArgTyrArgGlyThrAsnAspThrArgAsnIleSerPheAlaAla          .      1100         .         . ProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsn     .         .         .         .         . CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn          .         .      1200         . TrpIleGluAsnLysThrHisArgAsnTyrAlaProCysHisIle     .         .         .         .         . LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr          .         .         .      1300 LeuProProArgGluGlyGluLeuSerCysAsnSerThrValThr     .         .         .         .         . SerIleIleAlaAsnIleAspTrpGlnAsnAsnAsnGlnThrAsn          .         .         .         . IleThrPheSerAlaGluValAlaGluLeuTyrArgLeuGluLeu  1400         .         .         .         . GlyAspTyrLysLeuValGluIleThrProIleGlyPheAlaPro ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg     .      1500         .         .         . GlyValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGly          .         .         .         . SerAlaMetGlyAlaArgAlaSerLeuThrValSerAlaGlnSer     .         .      1600         .         . ArgThrLeuLeuAlaGlyIleValGlnGlnGlnGlnGlnLeuLeu          .         .         .         . AspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrp     .         .         .      1700         . GlyThrLysAsnLeuGlnAlaArgValThrAlaIleGluLysTyr                    .         .         . LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg     .         .         .         .      1800 GlnValCysHisThrThrValProTrpValAsnAspSerLeuAla          .         .         .         . ProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnVal     .         .         .         .         . ArgTyrLeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGln       1900         .         .         . IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer     .         .         .         .         . TrpAspIlePheGlyAsnTrpPheAspLeuThrSerTrpValLys          .      2000         .         . TyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeu     .         .         .         .         . ArgIleValIleTyrValValGlnMetLeuSerArgLeuArgLys          .         .      2100         . GlyTyrArgProValPheSerSerProProGlyTyrIleGlnGln IleHisIleHisLysAspArgGlyGlnProAlaAsnGluGluThr          .         .         .      2200 GluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrp     .         .         .         .         . ProIleAlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeu          .         .         .         . LeuThrArgLeuTyrSerIleCysArgAspLeuLeuSerArgSer  2300         .         .         .         . PheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArgAspTrpLeu          .         .         .         . ArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGln     .      2400         .         .         . GluAlaPheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAla          .         .         .         . GlyAlaCysArgGlyLeuTrpArgValLeuGluArgIleGlyArg     .         .      2500         .         . GlyIleLeuAlaValProArgArgIleArgGlnGlyAlaGluIle          .         .         .         . AlaLeuLeu***GlyThrAlaValSerAlaGlyArgLeuTyrGlu     .         .         .      2600         . TyrSerMetGluGlyProSerSerArgLysGlyGluLysPheVal          .         .         .         . GlnAlaThrLysTyrGly     .         .


18. A method for the in vitro detection of the presence of antibodies against anti-HIV-2 in a biological liquid, such as a serum, more particularly for the in vitro diagnosis of a potential or existing LAS or AIDS caused by HIV-2 type retrovirus, which comprises contacting a serum or other biological medium from the person to be diagnosed with a composition according to anyone of claims 8 to 11 or with an antigen according to anyone of claims 12 to 17, detecting the immunological conjuguate possibly formed between said anti-HIV-2-antibodies and the antigen or antigens used.
 19. The method of claim 18 which comprises achieving the detection of said immunological conjuguate by reacting said immunological conjuguate possibly formed with a labelled reagent formed either by human anti-immunoglobulin-antibodies or of a bacterial A protein, and by detecting the complexe formed between the reagent and said immunological conjuguate.
 20. Kit for the detection of anti-HIV-2-antibodies in a biological fluid, particularly of a person possibly carrying such antibodies, which comprises: a composition such as defined in anyone of claims 8 to 11 or an antigen such as defined in any of claims 12 to 17; and means for detecting the immunological complexe resulting from the immunological reaction between the antigen and said biological fluid.
 21. The kit of claim 21, whose means for detecting the immunological complexe formed comprises human anti-immunoglobulins or a protein A and a means for detecting the complexe formed between the anti-HIV-2 antibodies contained in the detected immunological conjuguate.
 22. Immunogenic compositions containing an envelope glycoprotein of HIV-2 retrovirus, such as gp140 of said retrovirus, or part of said glycoprotein, in association with a pharmaceutically acceptable vehicle appropriate for the constitution of vaccines effective against HIV-2.
 23. The composition of claim 22 which contains at least part of an immunogenic glycoprotein comprising the proteic backbone having the following sequence: ENVRN MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAlaSerAlaCys          .         .         .         . LeuValTyrCysThrGlnTyrValThrValPheTyrGlyValPro     .         .         .         .         . ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThrArgAsn        100         .         .         . ArgAspThrTrpGlyThrIleGlnCysLeuProAspAsnAspAsp     .         .         .         .         . TyrGlnGluIleThrLeuAsnValThrGluAlaPheAspAlaTrp          .       200         .         . AsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeu     .         .         .         .         . PheGluThrSerIleLysProCysValLysLeuThrProLeuCys          .         .       300         . ValAlaMetLysCysSerSerThrGluSerSerThrGlyAsnAsn     .         .         .         .         . ThrThrSerLysSerThrSerThrThrThrThrThrProThrAsp          .         .         .       400 GlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAsp     .         .         .         .         . AsnCysSerGlyLeuGlyGluGluGluThrIleAsnCysGlnPhe          .         .         .         . AsnMetThrGlyLeuGluArgAspLysLysLysGlnTyrAsnGlu   500         .         .         .         . ThrTrpTyrSerLysAspValValCysGluThrAsnAsnSerThr          .         .         .         . AsnGlnThrGlnCysTyrMetAsnHisCysAsnThrSerValIle     .       600         .         .         . ThrGluSerCysAspLysHisTyrTrpAspAlaIleArgPheArg          .         .         .         . TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr     .         .       700         .         . AsnTyrSerGlyPheAlaProAsnCysSerLysValValAlaSer          .         .         .         . ThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGly     .         .         .       800         . PheAsnGlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHis          .         .         .         . GlyArgAspAsnArgThrIleIleSerLeuAsnLysTyrTyrAsn     .         .         .         .       900 LeuSerLeuHisCysLysArgProGlyAsnLysThrValLysGln          .         .         .         . IleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnPro     .         .         .         .         . IleAsnLysArgProArgGlnAlaTrpCysTrpPheLysGlyLys       1000         .         .         . TrpLysAspAlaMetGlnGluValLysThrLeuAlaLysHisPro     .         .         .         .         . ArgTyrArgGlyThrAsnAspThrArgAsnIleSerPheAlaAla          .      1100         .         . ProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsn     .         .         .         .         . CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn          .         .      1200         . TrpIleGluAsnLysThrHisArgAsnTyrAlaProCysHisIle     .         .         .         .         . LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr          .         .         .      1300 LeuProProArgGluGlyGluLeuSerCysAsnSerThrValThr     .         .         .         .         . SerIleIleAlaAsnIleAspTrpGlnAsnAsnAsnGlnThrAsn          .         .         .         . IleThrPheSerAlaGluValAlaGluLeuTyrArgLeuGluLeu  1400         .         .         .         . GlyAspTyrLysLeuValGluIleThrProIleGlyPheAlaPro ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg     .      1500         .         .         . GlyValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGly          .         .         .         . SerAlaMetGlyAlaArgAlaSerLeuThrValSerAlaGlnSer     .         .      1600         .         . ArgThrLeuLeuAlaGlyIleValGlnGlnGlnGlnGlnLeuLeu          .         .         .         . AspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrp     .         .         .      1700         . GlyThrLysAsnLeuGlnAlaArgValThrAlaIleGluLysTyr                    .         .         . LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg     .         .         .         .      1800 GlnValCysHisThrThrValProTrpValAsnAspSerLeuAla          .         .         .         . ProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnVal     .         .         .         .         . ArgTyrLeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGln       1900         .         .         . IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer     .         .         .         .         . TrpAspIlePheGlyAsnTrpPheAspLeuThrSerTrpValLys          .      2000         .         . TyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeu     .         .         .         .         . ArgIleValIleTyrValValGlnMetLeuSerArgLeuArgLys          .         .      2100         . GlyTyrArgProValPheSerSerProProGlyTyrIleGlnGln IleHisIleHisLysAspArgGlyGlnProAlaAsnGluGluThr          .         .         .      2200 GluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrp     .         .         .         .         . ProIleAlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeu          .         .         .         . LeuThrArgLeuTyrSerIleCysArgAspLeuLeuSerArgSer  2300         .         .         .         . PheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArgAspTrpLeu          .         .         .         . ArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGln     .      2400         .         .         . GluAlaPheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAla          .         .         .         . GlyAlaCysArgGlyLeuTrpArgValLeuGluArgIleGlyArg     .         .      2500         .         . GlyIleLeuAlaValProArgArgIleArgGlnGlyAlaGluIle          .         .         .         . AlaLeuLeu***GlyThrAlaValSerAlaGlyArgLeuTyrGlu     .         .         .      2600         . TyrSerMetGluGlyProSerSerArgLysGlyGluLysPheVal          .         .         .         . GlnAlaThrLysTyrGly     .         .


24. The immunogenic composition of claim 22 or of claim 23 which is dosed in antigen in order to enable the administration of a dosage-unit of 10 to 500, particularly from 50 to 100 μg/kg of bodyweight.
 25. Monoclonal antibody characterized by its ability to specifically recognize one of the antigens according to anyone of claims 14 to
 17. 26. The secreting hybridomas of the monoclonal antibody of claim
 25. 27. Nucleic acids, optionally labelled, derived of part at least of RNA of HIV-2 virus or of one of its variance.
 28. The nucleic acid of claim 27, which contains at least part of the cDNA which corresponds with the entire genomic RNA of HIV-2 retrovirus.
 29. The nucleic acid of claim 27, which contains the nucleotide sequence: GTGGAAGGCGAGACTGAAAGCAAGAGGAATACCATTTAGTTAAAGGACAG GAACAGCTATACTTGGTCAGGGCAGGAAGTAACTAACAGAAACAGCTGAG ACTGCAGGGACTTTCCAGAAGGGGCTGTAACCAAGGGAGGGACATGGGAG GAGCTGGTGGGGAACGCCTCATATTCTCTGTATAATATACCCGCTGCTTG CATTGTACTTCAGTCGCTCTGCGGAGAGGCTGGCAGATTGAGCCCTGGAG GATCTCTCCAGCACTAGACGGATGAGCCTGGGTGCCCTGCTAGACTCTCA CCAGCACTTGGCCGGTGCTGGCAGACGGCCCCACGCTTGCCTGCTTAAAA ACCTTCCTTAATAAAGCTGCAGTAGAAGCA


30. The nucleic acid of claim 27, which contains a nucleotidic sequence coding for at least part of the aminoacid sequence indicated hereafter: GAGRODN MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGlu          ·         ·         ·         · LeuGluArgIleArgLeuArgProGlyGlyLysLysLysTyrArg     ·         ·         ·         ·         · LeuLysHisIleValTrpAlaAlaAsnLysLeuAspArgPheGly        100         ·         ·         · LeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLysIle     ·         ·         ·         ·         · LeuThrValLeuAspProMetValProThrGlySerGluAsnLeu          ·       200         ·         ·      LysSerLeuPheAsnThrValCysValIleTrpCysIleHisAla     ·         ·         ·         ·         · GluGluLysValLysAspThrGluGlyAlaLysGlnIleValArg          ·         ·       300         · ArgHisLeuValAlaGluThrGlyThrAlaGluLysNetProSer     ·         ·         ·         ·         · ThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyr          ·         ·         ·       400 ProValGlnHisValGlyGlyAsnTyrThrHisIleProLeuSer     ·         ·         ·         ·         · ProArgThrLeuAsnAlaTrpValLysLeuValGluGluLysLys          ·         ·         ·         · PheGlyAlaGluValValProGlyPheGlnAlaLeuSerGluGly   500         ·         ·         ·         · CysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAsp          ·         ·         ·         · HisGlnAlaAlaMetGlnIleIleArgGluIleIleAsnGluGlu     ·       600         ·         ·         · AlaAlaGluTrpAspValGlnHisProIleProGlyProLeuPro          ·         ·         ·         · AlaGlyGlnLeuArgGluProArgGlySerAspIleAlaGlyThr     ·         ·       700         ·         · ThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGln AsnProValProValGlyAsnIleTyrArgArgTrpIleGlnIle     ·         ·         ·       800         · GlyLeuGlnLysCysValArgMetTyrAsnProThrAsnIleLeu          ·         ·         ·         · AspIleLysGlnGlyProLysGluProPheGlnSerTyrValAsp     ·         ·         ·         ·       900 ArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaVal          ·         ·         ·         · LysAsnTrpMetThrGlnThrLeuLeuValGlnAsnAlaAsnPro     ·         ·         ·         ·          AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu       1000         ·         ·         · GluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGlyGln     ·         ·         ·         ·         · LysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyPro          ·      1100         ·         · AlaProIleProPheAlaAlaAlaGlnGlnArgLysAlaPheLys     ·         ·         ·         ·         · CysTrpAsnCysGlyLysGluGlyHisSerAlaArgGlnCysArg          ·         ·      1200         · AlaProArgArgGlnGlyCysTrpLysCysGlyLysProGlyHis     ·         ·         ·         ·         · IleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeu          ·         ·         ·      1300 GlyProTrpGlyLysLysProArgAsnPheProValAlaGlnVal     ·         ·         ·         ·         · ProGlnGlyLeuThrProThrAlaProProValAspProAlaVal          ·         ·         ·         · AspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArgGlu  1400         ·         ·         ·         · GlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHis          ·         ·         ·         · LeuGluGlnGlyGluThrProTyrArgGluProProThrGluAsp     ·      1500         ·         · LeuLeuHisLeuAsnSerLeuPheGlyLysAspGln          ·         ·         ·


31. The nucleic acid of claim 27, which contains a nucleotidic sequence coding for at least part of the aminoacid sequence indicated hereafter:                              |ArgLysAlaPheLys                              |                              |    ·         · CysTrpAsnCysGlyLysGluGlyHisSerAlaArgGlnCysArg          ·         ·      1200         · AlaProArgArgGlnGlyCysTrpLysCysGlyLysProGlyHis     ·         ·         ·         ·         · IleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeu          ·         ·         ·      1300 GlyProTrpGlyLysLysProArgAsnPheProValAlaGlnVal     ·         ·         ·         ·         · ProGlnGlyLeuThrProThrAlaProProValAspProAlaVal          ·         ·         ·         · AspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArgGlu  1400         ·         ·         ·         · GlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHis          ·         ·         ·         · LeuGluGlnGlyGluThrProTyrArgGluProProThrGluAsp     ·      1500         ·         ·         · LeuLeuHisLeuAsnSerLeuPheGlyLysAspGln


32. The nucleic acid of claim 27, which contains a nucleotidic sequence coding for at least part of the aminoacid sequence indicated hereafter: MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGlu          ·         ·         ·         · LeuGluArgIleArgLeuArgProGlyGlyLysLysLysTyrArg     ·         ·         ·         ·         · LeuLysHisIleValTrpAlaAlaAsnLysLeuAspArgPheGly        100         ·         ·         · LeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLysIle     ·         ·         ·         ·         · LeuThrValLeuAspProNetValProThrGlySerGluAsnLeu          ·       200         ·         · LysSerLeuPheAsnThrValCysValIleTrpCysIleHisAla     ·         ·         ·         ·         · GluGluLysValLysAspThrGluGlyAlaLysGlnIleValArg          ·         ·       300         · ArgHisLeuValAlaGluThrGlyThrAlaGluLysMetProSer     ·         ·         ·         ·         · ThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyr                              ·       400


33. The nucleic acid of claim 27, which contains a nucleotidic sequence coding for at least part of the aminoacid sequence indicated hereafter: ProValGlnHisValGlyGlyAsnTyrThrHisIleProLeuSer     ·         ·         ·         ·         · ProArgThrLeuAsnAlaTrpValLysLeuValGluGluLysLys          ·         ·         ·         · PheGlyAlaGluValValProGlyPheGlnAlaLeuSerGluGly   500         ·         ·         ·         · CysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAsp          ·         ·         ·         · HisGlnAlaAlaMetGlnIleIleArgGluIleIleAsnGluGlu     ·       600         ·         ·         · AlaAlaGluTrpAspValGlnHisProIleProGlyProLeuPro          ·         ·         ·         · AlaGlyGlnLexArgGluProArgGlySerAspIleAlaGlyThr     ·         ·       700         ·         · ThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGln AsnProValProValGlyAsnIleTyrArgArgTrpIleGlnIle     ·         ·         ·       800         · GlyLeuGlnLysCysValArgMetTyrAsnProThrAsnIleLeu          ·         ·         ·         · AspIleLysGlnGlyProLysGluProPheGlnSerTyrValArp     ·         ·         ·         ·       900 ArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaVal          ·         ·         ·         · LysAsnTrpMetThrGlnThrLeuLeuValGlnAsnAlaAsnPro     ·         ·         ·         ·         · AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu       1000         ·         ·         · GluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGlyGln     ·         ·         ·         ·         · LysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyPro          ·      1100         ·         · AlaProIleProPheAlaAlaAlaGlnGln


34. The nucleic acid of claim 27, which contains a nucleotidic sequence coding for at least part of the aminoacid sequence indicated hereafter: ENVRN MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAlaSerAlaCys          ·         ·         ·         · LeuValTyrCysThrGlnTyrValThrValPheTyrGlyValPro     ·         ·         ·         ·         · ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThrArgAsn        100         ·         ·         · ArgAspThrTrpGlyThrIleGlnCysLeuProAspAstAspAsp     ·         ·         ·         ·         · TyrGlnGluIleThrLeuAsnValThrGluAlaPheAspAlaTrp          ·       200         ·         · AsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeu     ·         ·         ·         ·         · PheGluThrSerIleLysProCysValLysLeuThrProLeuCys          ·         ·       300         · ValAlaMetLysCysSerSerThrGluSerSerThrGlyAsnAsn     ·         ·         ·         ·         · ThrThrSerLysSerThrSerThrThrThrThrThrProThrAsp          ·         ·         ·       400 GlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAsp     ·         ·         ·         ·         · AsnCysSerGlyLeuGlyGluGluGluThrIleAsnCysGlnPhe          ·         ·         ·         · AsnMetThrGlyLeuGluArgAspLysLysLysGlnTyrAsnGlu   500         ·         ·         ·         · ThrTrpTyrSerLysAspValValCysGluThrAsnAsnSerThr          ·         ·         ·         · AsnGlnThrGlnCysTyrMetAsnEisCysAsnThrSerValIle     ·       600         ·         ·         · ThrGluSerCysAspLysHisTyrTrpAspAlaIleArgPheArg          ·         ·         ·         · TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr     ·         ·       700         ·         · AsnTyrSerGlyPheAlaProAsnCysSerLysValValAlaSer ThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGly     ·         ·         ·       800         · PheAsnGlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHis          ·         ·         ·         · GlyArgAspAsnArgThrIleIleSerLeuAsnLysTyrTyrAsn     ·         ·         ·         ·       900 LeuSerLeuHisCysLysArgProGlyAsnLysThrValLysGln          ·         ·         ·         · IleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnPro     ·         ·         ·         ·         · IleAsnLysArgProArgGlnAlaTrpCysTrpPheLysGlyLys       1000         ·         ·         · TrpLysAspAlaMetGlnGluValLysThrLeuAlaLysHisPro     ·         ·         ·         ·         · ArgTyrArgGlyThrAsnAspThrArgAsnIleSerPheAlaAla          ·      1100         ·         · ProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsn     ·         ·         ·         ·         · CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn          ·         ·      1200         · TrpIleGluAsnLysThrHisArgAsnTyrAlaProCysHisIle     ·         ·         ·         ·         · LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr          ·         ·         ·      1300 LeuProProArgGluGlyGluLeuSerCysAsnSerThrValThr     ·         ·         ·         ·         · SerIleIleAlaAsnIleAspTrpGlnAsnAstAsnGlnThrAsn          ·         ·         ·         · IleThrPheSerAlaGluValAlaGluLeuTyrArgLeuGluLeu  1400         ·         ·         ·         · GlyAspTyrLysLeuValGluIleThrProIleGlyPheAlaPro ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg     ·      1500         ·         ·         · GlyValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGly          ·         ·         ·         · SerAlaMetGlyAlaArgAlaSerLeuThrValSerAlaGlnSer     ·         ·      1600         ·         · ArgThrLeuLeuAlaGlyIleValGlnGlnGlnGlnGlnLeuLeu          ·         ·         ·         · AspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrp     ·         ·         ·      1700         · GlyThrLysAsnLeuGlnAlaArgValThrAlaIleGluLysTyr                    ·         ·         · LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg     ·         ·         ·         ·      1800 GlnValCysHisThrThrValProTrpValAsnAspSerLeuAla          ·         ·         ·         · ProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnVal     ·         ·         ·         ·         · ArgTyrLeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGln       1900         ·         ·         · IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer     ·         ·         ·         ·         · TrpAspIlePheGlyAsnTrpPheAspLeuThrSerTrpValLys          ·      2000         ·         · TyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeu     ·         ·         ·         ·         · ArgIleValIleTyrValValGlnMetLeuSerArgLeuArgLys          ·         ·      2100         · GlyTyrArgProValPheSerSerProProGlyTyrIleGlnGln IleEisIleEisLysAspArgGlyGlnProAlaAsnGluGluThr          ·         ·         ·      2200 GluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrp     ·         ·         ·         ·         · ProIleAlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeu          ·         ·         ·         · LeuThrArgLeuTyrSerIleCysArgAspLeuLeuSerArgSer  2300         ·         ·         ·         · PheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArgAspTrpLeu          ·         ·         ·         · ArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGln     ·      2400         ·         ·         · GluAlaPheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAla          ·         ·         ·         · GlyAlaCysArgGlyLeuTrpArgValLeuGluArgIleGlyArg     ·         ·      2500         ·         · GlyIleLeuAlaValProArgArgIleArgGlnGlyAlaGluIle          ·         ·         ·         · AlaLeuLeu***GlyThrAlaValSerAlnGlyArgLeuTyrGlu     ·         ·         ·      2600         · TyrSerMetGluGlyProSerSerArgLysGlyGluLysPheVal          ·         ·         ·         · GlnAlaThrLysTyrGly     ·         ·


35. The nucleic acid of anyone of claims 28 to 34 which is formed a recombinant nucleic acid comprising a nucleic acid from a vector and in which said cDNA or part of said cDNA is inserted.
 36. The recombinant nucleic acid of claim 35 which is labelled.
 37. A process for the detection of HIV-2 retrovirus or of its RNA in a biological liquid or tissue, particularly for the in vitro diagnosis in man of the potentiality or existence of LAS or of AIDS, which comprises contacting nucleic acids contained in said biological liquid or tissue with a probe containing a nucleic acid according to anyone of claims 28 to 36 under stringent hybridization conditions for the time necessary for said hybridization to occur, washing the hybride formed with a solution ensuring the preservation of said stringent conditions, and detecting the hybride formed.
 38. A process for the production of HIV-2 retrovirus which comprises culturing human T4 lymphocytes or permanent cell lines derived from said T4 lymphocytes and carrying the T4 phenotype, which lymphocytes or cell lines had previously been infected with an isolate of HIV-2 virus and, particularly when the level of reverse transcriptase activity has reached a determined threshold, recovering and purifying the amounts of virus released in the culture medium of said lymphocytes or cell lines, particularly by differential centrifugation in a gradient of sucrose or metrizamide.
 39. A process for the production of specific antigen of HIV-2 retrovirus which comprises lysing, particularly by means of detergent such as SDS (for instance 0.1% SDS in a RIPA buffer) and recovering the lysate containing said antigens;
 40. Process for the production of one of the above defined proteins (p12, p16 or p26) or of a protein having the structure of gp140 or of determined parts of said proteins, which process comprises inserting the corresponding nucleic acid sequence in a vector capable of transforming an appropriate host,enabling the expression of an insert containing in said vector, transforming said host by said vector which comprises the said nucleotidic sequence, culturing the transformed cell lines host, recovering and purifying the expressed protein.
 41. Process for the production of a hybridization probe for the detection of the RNA of HIV-2 retrovirus which comprises a DNA sequence, particularly according to anyone of claims 27 to 35, in a cloning vector by in vitro recombination, cloning the modified vector obtained in a competent cellular host, and recovering the DNA-recombinants obtained. 